PMID	chemical	trigger	target	context_sentence
25736031	Fructose	induce	insulin resistance	Fructose diets have been shown to induce insulin resistance and to alter liver metabolism and gut barrier function, ultimately leading to non-alcoholic fatty liver disease.
25736031	Fructose	alter	liver metabolism and gut barrier function	Fructose diets have been shown to induce insulin resistance and to alter liver metabolism and gut barrier function, ultimately leading to non-alcoholic fatty liver disease.
25736031	Citrulline	improve	insulin sensitivity	Citrulline, Glutamine and Arginine may improve insulin sensitivity and have beneficial effects on gut trophicity.
25736031	Glutamine	improve	insulin sensitivity	Citrulline, Glutamine and Arginine may improve insulin sensitivity and have beneficial effects on gut trophicity.
25736031	Arginine	improve	insulin sensitivity	Citrulline, Glutamine and Arginine may improve insulin sensitivity and have beneficial effects on gut trophicity.
25736031	fructose	alter	glucose homeostasis	In these experimental isonitrogenous fructose diet conditions, fructose led to steatosis with dyslipidemia but without altering glucose homeostasis, liver function or gut permeability.
25736031	Fructose	decrease	Bifidobacterium and Lactobacillus	Fructose significantly decreased Bifidobacterium and Lactobacillus and tended to increase endotoxemia.
25736031	Fructose	increase	endotoxemia	Fructose significantly decreased Bifidobacterium and Lactobacillus and tended to increase endotoxemia.
25736031	Citrulline	prevent	hypertriglyceridemia	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	Arginine	prevent	hypertriglyceridemia	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	Glutamine	prevent	hypertriglyceridemia	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	Citrulline	attenuate	liver fat accumulation	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	Arginine	attenuate	liver fat accumulation	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	Glutamine	attenuate	liver fat accumulation	Arginine and Glutamine supplements were ineffective but Citrulline supplementation prevented hypertriglyceridemia and attenuated liver fat accumulation.
25736031	nitrogen	attenuate	fructose-induced non-alcoholic fatty liver disease	While nitrogen supply alone can attenuate fructose-induced non-alcoholic fatty liver disease, Citrulline appears to act directly on hepatic lipid metabolism by partially preventing hypertriglyceridemia and steatosis.
25736031	Citrulline	attenuate	fructose-induced non-alcoholic fatty liver disease	While nitrogen supply alone can attenuate fructose-induced non-alcoholic fatty liver disease, Citrulline appears to act directly on hepatic lipid metabolism by partially preventing hypertriglyceridemia and steatosis.
25736031	Citrulline	prevent	hypertriglyceridemia and steatosis	While nitrogen supply alone can attenuate fructose-induced non-alcoholic fatty liver disease, Citrulline appears to act directly on hepatic lipid metabolism by partially preventing hypertriglyceridemia and steatosis.
26396156	carbohydrate	waste	disorders, metabolic disease, and nonalcoholic fatty liver disease	3,3',4,4',5-Pentachlorobiphenyl (PCB126), a dioxin-like polychlorinated biphenyl (PCB) and a potent aryl hydrocarbon receptor (AhR) agonist, is implicated in the disruption of both carbohydrate and lipid metabolism which ultimately leads to wasting disorders, metabolic disease, and nonalcoholic fatty liver disease.
26396156	Pparα	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis	Additionally, transcript levels of Pparα, and its targets acyl-CoA oxidase (Acox1) and hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), were also downregulated, indicating changes in peroxisomal fatty acid oxidation and ketogenesis.
26396156	acyl-CoA oxidase	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis	Additionally, transcript levels of Pparα, and its targets acyl-CoA oxidase (Acox1) and hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), were also downregulated, indicating changes in peroxisomal fatty acid oxidation and ketogenesis.
26396156	Acox1	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis	Additionally, transcript levels of Pparα, and its targets acyl-CoA oxidase (Acox1) and hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), were also downregulated, indicating changes in peroxisomal fatty acid oxidation and ketogenesis.
26396156	hydroxy-3-methylglutaryl-CoA synthase 2	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis	Additionally, transcript levels of Pparα, and its targets acyl-CoA oxidase (Acox1) and hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), were also downregulated, indicating changes in peroxisomal fatty acid oxidation and ketogenesis.
26396156	Hmgcs2	indicate	changes in peroxisomal fatty acid oxidation and ketogenesis	Additionally, transcript levels of Pparα, and its targets acyl-CoA oxidase (Acox1) and hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), were also downregulated, indicating changes in peroxisomal fatty acid oxidation and ketogenesis.
26396156	PCB126-induced	decrease	serum glucose caused by decreased hepatic glucose production	These results indicate that PCB126-induced wasting and steatosis are preceded initially by (1) decreased serum glucose caused by decreased hepatic glucose production, followed by (2) decreased peroxisomal fatty acid oxidation.
26396156	PCB126-induced	decrease	peroxisomal fatty acid oxidation	These results indicate that PCB126-induced wasting and steatosis are preceded initially by (1) decreased serum glucose caused by decreased hepatic glucose production, followed by (2) decreased peroxisomal fatty acid oxidation.
26640164	Tetracycline	cause	hepatic steatosis, and	Tetracycline can cause hepatic steatosis, and ER stress may be involved in tetracycline-induced fatty liver.
26640164	bicyclol	attenuate	tetracycline-induced fatty liver	Therefore, this study was performed to investigate the underlying mechanisms associated with ER stress and apoptosis, by which bicyclol attenuated tetracycline-induced fatty liver in mice.
26640164	tetracycline	evaluate	liver injuries	At 6 h and 24 h after single dose of tetracycline injection, serum ALT, AST, TG, CHO and hepatic histopathological examinations were performed to evaluate liver injuries.
26640164	serum ALT	evaluate	liver injuries	At 6 h and 24 h after single dose of tetracycline injection, serum ALT, AST, TG, CHO and hepatic histopathological examinations were performed to evaluate liver injuries.
26640164	AST	evaluate	liver injuries	At 6 h and 24 h after single dose of tetracycline injection, serum ALT, AST, TG, CHO and hepatic histopathological examinations were performed to evaluate liver injuries.
26640164	TG	evaluate	liver injuries	At 6 h and 24 h after single dose of tetracycline injection, serum ALT, AST, TG, CHO and hepatic histopathological examinations were performed to evaluate liver injuries.
26640164	CHO	evaluate	liver injuries	At 6 h and 24 h after single dose of tetracycline injection, serum ALT, AST, TG, CHO and hepatic histopathological examinations were performed to evaluate liver injuries.
26640164	bicyclol	alleviate	hepatic apoptosis and the gene expression of caspase-3	In addition, bicyclol remarkably alleviated hepatic apoptosis and the gene expression of caspase-3, and increased the gene expression of XIAP.
26640164	bicyclol	increase	the gene expression of XIAP	In addition, bicyclol remarkably alleviated hepatic apoptosis and the gene expression of caspase-3, and increased the gene expression of XIAP.
26640164	bicyclol	protect	tetracycline-induced fatty liver	These results suggested that bicyclol protected tetracycline-induced fatty liver partly due to its ability of anti-apoptosis associated with ER stress.
27062444	Peroxisome proliferator-activated receptor gamma	regulate	lipogenesis and lipid accumulation	Peroxisome proliferator-activated receptor gamma (PPARγ) signaling has been shown to regulate lipogenesis and lipid accumulation.
27062444	Lieber-DeCarli alcohol	control	liquid diet	To determine the role of hepatic PPARγ signaling on ALD, wild-type (WT) and hepatocyte-specific PPARγ knockdown (PPARγ∆Hep) mice were fed a modified Lieber-DeCarli alcohol or isocaloric maltose dextrin control liquid diet for 8 weeks to induce ALD.
27062444	maltose dextrin	control	liquid diet	To determine the role of hepatic PPARγ signaling on ALD, wild-type (WT) and hepatocyte-specific PPARγ knockdown (PPARγ∆Hep) mice were fed a modified Lieber-DeCarli alcohol or isocaloric maltose dextrin control liquid diet for 8 weeks to induce ALD.
27062444	hepatic PPARγ	alleviate	alcohol-induced lipid accumulation	Knockdown of hepatic PPARγ significantly alleviated alcohol-induced lipid accumulation and abolished the up-regulation of FASN, DGAT1, and DGAT2.
27062444	hepatic PPARγ	abolish	the up-regulation of FASN, DGAT1, and DGAT2	Knockdown of hepatic PPARγ significantly alleviated alcohol-induced lipid accumulation and abolished the up-regulation of FASN, DGAT1, and DGAT2.
27062444	FL83B cells	decrease	ethanol (EtOH)-, linoleic acid-, and EtOH plus linoleic acid-induced lipid accumulation	Silencing of PPARγ in FL83B cells significantly decreased ethanol (EtOH)-, linoleic acid-, and EtOH plus linoleic acid-induced lipid accumulation.
27108203	PFOS	increase	the transcriptional expression of nuclear receptors	Quantitative PCR assay further indicated that PFOS significantly increase the transcriptional expression of nuclear receptors (nr1h3, rara, rxrgb, nr1l2) and the genes associated with fatty acid oxidation (acox1, acadm, cpt1a).
27108203	PFOS	decrease	liver ATP content and serum level of VLDL/LDL lipoprotein in males	In addition, chronic PFOS exposure significantly decreased liver ATP content and serum level of VLDL/LDL lipoprotein in males.
27108203	PFOS	induce	hepatic steatosis in zebrafish	Taken together, these findings suggest that chronic PFOS exposure induces hepatic steatosis in zebrafish via disturbing lipid biosynthesis, fatty acid β-oxidation and excretion of VLDL/LDL lipoprotein, and also demonstrate the validity of using zebrafish as an alternative model for PFOS chronic toxicity screening.
27108203	PFOS	disturb	lipid biosynthesis, fatty acid β-oxidation and excretion of VLDL/LDL lipoprotein	Taken together, these findings suggest that chronic PFOS exposure induces hepatic steatosis in zebrafish via disturbing lipid biosynthesis, fatty acid β-oxidation and excretion of VLDL/LDL lipoprotein, and also demonstrate the validity of using zebrafish as an alternative model for PFOS chronic toxicity screening.
27108203	PFOS	demonstrate	the validity of using zebrafish as an alternative model for PFOS chronic toxicity screening	Taken together, these findings suggest that chronic PFOS exposure induces hepatic steatosis in zebrafish via disturbing lipid biosynthesis, fatty acid β-oxidation and excretion of VLDL/LDL lipoprotein, and also demonstrate the validity of using zebrafish as an alternative model for PFOS chronic toxicity screening.
27124661	ethanol	dysregulate	PTEN/Akt signaling	In murine models, chronic ethanol consumption dysregulates PTEN/Akt signaling.
27124661	tensin homolog	possess	constitutive activation of Akt(s	Hepatospecific deletion of phosphatase and tensin homolog deleted on chromosome 10 (PTENLKO) mice possess constitutive activation of Akt(s) and increased de novo lipogenesis resulting in increased hepatocellular steatosis.
27124661	tensin	possess	constitutive activation of Akt(s	Hepatospecific deletion of phosphatase and tensin homolog deleted on chromosome 10 (PTENLKO) mice possess constitutive activation of Akt(s) and increased de novo lipogenesis resulting in increased hepatocellular steatosis.
27124661	tensin homolog	increase	de novo lipogenesis resulting in increased hepatocellular steatosis	Hepatospecific deletion of phosphatase and tensin homolog deleted on chromosome 10 (PTENLKO) mice possess constitutive activation of Akt(s) and increased de novo lipogenesis resulting in increased hepatocellular steatosis.
27124661	tensin	increase	de novo lipogenesis resulting in increased hepatocellular steatosis	Hepatospecific deletion of phosphatase and tensin homolog deleted on chromosome 10 (PTENLKO) mice possess constitutive activation of Akt(s) and increased de novo lipogenesis resulting in increased hepatocellular steatosis.
27124661	ethanol	increase	ALT, liver triglycerides and steatosis	In the control PTENf/f animals, ethanol significantly increased ALT, liver triglycerides and steatosis.
27124661	ethanol	decrease	hepatocellular damage	In contrast, chronic ethanol consumption in PTENLKO mice decreased hepatocellular damage when compared to PTENLKO pair-fed controls.
27124661	ethanol	have	no effect in PTENLKO animals	Consumption of ethanol elevated protein carbonylation in PTENf/f animals but had no effect in PTENLKO animals.
27220557	FO	attenuate	the ethanol-induced hepatic lipid accumulation in mice	In this study, we assessed the potential protective effects of ALA-rich flaxseed oil (FO) on ethanol-induced hepatic steatosis and observed that dietary FO supplementation effectively attenuated the ethanol-induced hepatic lipid accumulation in mice.
27220557	Ethanol	stimulate	adipose lipolysis	Ethanol exposure stimulated adipose lipolysis but reduced fatty acid/lipid uptake, which were normalized by FO.
27220557	Ethanol	reduce	fatty acid/lipid uptake, which were normalized by FO	Ethanol exposure stimulated adipose lipolysis but reduced fatty acid/lipid uptake, which were normalized by FO.
27220557	FO	normalize	lipid metabolism in adipose tissue	Our investigations into the corresponding mechanisms demonstrated that the ameliorating effect of FO might be associated with the lower endoplasmic reticulum stress and normalized lipid metabolism in adipose tissue.
27220557	alcohol	stimulate	hepatic fatty acid uptake and triglyceride synthesis, which were attenuated by FO	In the liver, alcohol exposure stimulated hepatic fatty acid uptake and triglyceride synthesis, which were attenuated by FO.
27220557	FO	upregulate	plasma adiponectin concentration	Additionally, dietary FO upregulated plasma adiponectin concentration, hepatic adiponectin receptor 2 expression, and the activation of hepatic adenosine monophosphate-activated protein kinase.
27220557	FO	upregulate	hepatic adiponectin receptor 2 expression	Additionally, dietary FO upregulated plasma adiponectin concentration, hepatic adiponectin receptor 2 expression, and the activation of hepatic adenosine monophosphate-activated protein kinase.
27220557	FO	improve	lipid homeostasis	Collectively, dietary FO protects against alcoholic hepatic steatosis by improving lipid homeostasis at the adipose tissue-liver axis, suggesting that dietary ALA-rich flaxseed oil might be a promising approach for prevention of alcoholic fatty liver.
27614967	ginsenosides	reduce	TG content (9.69±0.22 μg/mg protein vs. 4.93±0.49 μg/mg protein, P<0.01), and ROS formation (7254.8±385.7 vs. 5825.2±375.9, P<0.01)	However, ginsenosides significantly reduced TG content (9.69±0.22 μg/mg protein vs. 4.93±0.49 μg/mg protein, P<0.01), and ROS formation (7254.8±385.7 vs. 5825.2±375.9, P<0.01).
27614967	ginsenosides	down-regulate	CYP2E1 expression (P<0.01)	Furthermore, ginsenosides could down-regulate CYP2E1 expression (P<0.01) and upregulate PPARα expression (P<0.01) in ethanol-treated cells.
27614967	ginsenosides	upregulate	PPARα expression (P<0.01) in ethanol-treated cells	Furthermore, ginsenosides could down-regulate CYP2E1 expression (P<0.01) and upregulate PPARα expression (P<0.01) in ethanol-treated cells.
27614967	Ginsenosides	prevent	ethanol-induced hepatocyte steatosis in vitro related to the inhibition of oxidative stress and the improvement of mitochondrial function	Ginsenosides could prevent ethanol-induced hepatocyte steatosis in vitro related to the inhibition of oxidative stress and the improvement of mitochondrial function.
27614967	CYP2E1	play	an important role in the protective effect of ginsenosides against lipid accumulation	In addition, the modulation of CYP2E1 and PPARα expression may also play an important role in the protective effect of ginsenosides against lipid accumulation.
27614967	PPARα	play	an important role in the protective effect of ginsenosides against lipid accumulation	In addition, the modulation of CYP2E1 and PPARα expression may also play an important role in the protective effect of ginsenosides against lipid accumulation.
27627966	alcohol	cause	hepatic lipid accumulation	Previous studies demonstrated that acute alcohol intoxication caused hepatic lipid accumulation.
27627966	alcohol	cause	hepatic lipid accumulation in Tlr4-wild-type mice but not in Tlr4-mutant mice	The present study showed that acute alcohol intoxication caused hepatic lipid accumulation in Tlr4-wild-type mice but not in Tlr4-mutant mice.
27692001	fatty liver	exhibit	hyperketonemia, oxidative stress,	Dairy cows with fatty liver or ketosis exhibit hyperketonemia, oxidative stress, and a low rate of very low density lipoprotein (VLDL) assembly, and there may be a potential link among these characteristics.
27692001	AcAc	decrease	the mRNA expression and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px),	AcAc treatment decreased the mRNA expression and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), and significantly increased malondialdehyde (MDA) content, indicative of oxidative stress.
27692001	AcAc	increase	malondialdehyde (MDA) content, indicative of oxidative stress	AcAc treatment decreased the mRNA expression and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), and significantly increased malondialdehyde (MDA) content, indicative of oxidative stress.
27692001	AcAc	down-regulate	the mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and low density lipoprotein receptor (LDLR), which thus decreased VLDL assembly	Furthermore, AcAc treatment significantly down-regulated the mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and low density lipoprotein receptor (LDLR), which thus decreased VLDL assembly and increased triglyceride (TG) accumulation in these bovine hepatocytes.
27692001	LDLR	decrease	VLDL assembly	Furthermore, AcAc treatment significantly down-regulated the mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and low density lipoprotein receptor (LDLR), which thus decreased VLDL assembly and increased triglyceride (TG) accumulation in these bovine hepatocytes.
27692001	AcAc	increase	triglyceride (TG) accumulation in these bovine hepatocytes	Furthermore, AcAc treatment significantly down-regulated the mRNA expression of apolipoprotein B100 (ApoB100), apolipoprotein E (ApoE), and low density lipoprotein receptor (LDLR), which thus decreased VLDL assembly and increased triglyceride (TG) accumulation in these bovine hepatocytes.
27692001	NAC	relieve	AcAc-induced oxidative stress	Importantly, NAC relieved AcAc-induced oxidative stress and increased VLDL assembly.
27692001	NAC	increase	VLDL assembly	Importantly, NAC relieved AcAc-induced oxidative stress and increased VLDL assembly.
27692001	VLDL	increase	TG accumulation in bovine hepatocytes	In summary, these results suggest that AcAc-induced oxidative stress affects the assembly of VLDL, which increases TG accumulation in bovine hepatocytes.
27837167	ligustrazine	attenuate	alcohol-induced hepatic steatosis and in vitro study	Our previous in vivo study showed that ligustrazine, a major active alkaloid isolated from Ligusticum chuanxiong Hort, attenuated alcohol-induced hepatic steatosis and in vitro study revealed that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation might be a prerequisite.
27837167	Nrf2	establish	Nrf2-knockdown mice	Nrf2 shRNA lentivirus was introduced to establish Nrf2-knockdown mice.
27837167	Nrf2	aggravate	alcoholic liver injury	Results showed that Nrf2 knockdown aggravated alcoholic liver injury and abolished the protective effect of ligustrazine, evidenced by elevated serum biomarkers and severe liver inflammation.
27837167	Nrf2	abolish	the protective effect of ligustrazine, evidenced by elevated serum biomarkers and severe liver inflammation	Results showed that Nrf2 knockdown aggravated alcoholic liver injury and abolished the protective effect of ligustrazine, evidenced by elevated serum biomarkers and severe liver inflammation.
27837167	Ligustrazine	ameliorate	hepatic steatosis	Ligustrazine impressively ameliorated hepatic steatosis through inhibiting hepatic sterol regulatory element-binding protein-1c and inducing peroxisome proliferator-activated receptor-alpha, which was abrogated by Nrf2 knockdown.
27837167	Ligustrazine	inhibit	hepatic sterol regulatory element-binding protein-1c and inducing peroxisome proliferator-activated receptor-alpha, which was abrogated by Nrf2 knockdown	Ligustrazine impressively ameliorated hepatic steatosis through inhibiting hepatic sterol regulatory element-binding protein-1c and inducing peroxisome proliferator-activated receptor-alpha, which was abrogated by Nrf2 knockdown.
27837167	Noteworthily	reinforce	the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α)	Noteworthily, Nrf2 knockdown apparently reinforced the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α).
27837167	Nrf2	reinforce	the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α)	Noteworthily, Nrf2 knockdown apparently reinforced the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1α).
27837167	Ligustrazine	weaken	the stimulation of alcohol on HIF-1α expression, which was abrogated by Nrf2 shRNA lentivirus	Ligustrazine weakened the stimulation of alcohol on HIF-1α expression, which was abrogated by Nrf2 shRNA lentivirus.
27837167	Nrf2	abolish	the inhibitory effect of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	dimethyloxalylglycine	abolish	the inhibitory effect of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	HIF-1α	abolish	the inhibitory effect of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	HIF-1α	mimic	the role of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	Nrf2	mimic	the role of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	dimethyloxalylglycine	mimic	the role of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	HIF-1α	mimic	the role of ligustrazine	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	HIF-1α	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	Nrf2	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	dimethyloxalylglycine	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	HIF-1α	rescue	the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes	Gain- or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1α agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1α siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes.
27837167	ligustrazine	attenuate	alcohol-induced hepatic steatosis	Taken together, we concluded that ligustrazine attenuated alcohol-induced hepatic steatosis via a Nrf2/HIF-1α pathway-dependent mechanism.
28131861	Cyp2a5	feed	the Lieber-Decarli ethanol diet	Cyp2a5 knockout (Cyp2a5 Mice were fed the Lieber-Decarli ethanol diet to induce alcoholic fatty liver.
28131861	Cyp2a5 Mice	feed	the Lieber-Decarli ethanol diet	Cyp2a5 knockout (Cyp2a5 Mice were fed the Lieber-Decarli ethanol diet to induce alcoholic fatty liver.
28131861	Cyp2a5	induce	alcoholic fatty liver	Cyp2a5 knockout (Cyp2a5 Mice were fed the Lieber-Decarli ethanol diet to induce alcoholic fatty liver.
28131861	Cyp2a5 Mice	induce	alcoholic fatty liver	Cyp2a5 knockout (Cyp2a5 Mice were fed the Lieber-Decarli ethanol diet to induce alcoholic fatty liver.
28366540	VPA	enhance	the efficiency of fatty acid uptake mediated by CD36	Furthermore, VPA treatment remarkably enhanced the efficiency of fatty acid uptake mediated by CD36, while this effect was abolished by the interference with CD36-specific siRNA.
28366540	VPA	increase	DGAT2 expression	Also, VPA treatment significantly increased DGAT2 expression as a result of the inhibition of mitogen-activated protein kinase kinase (MEK) - extracellular regulated kinase (ERK) pathway; however, DGAT2 knockdown significantly alleviated VPA-induced intracellular lipid accumulation.
28366540	DGAT2	alleviate	VPA-induced intracellular lipid accumulation	Also, VPA treatment significantly increased DGAT2 expression as a result of the inhibition of mitogen-activated protein kinase kinase (MEK) - extracellular regulated kinase (ERK) pathway; however, DGAT2 knockdown significantly alleviated VPA-induced intracellular lipid accumulation.
28366540	CD36	offer	novel therapeutic strategies to combat VPA-induced hepatotoxicity	Overall, VPA-triggered over-regulation of CD36 and DGAT2 could be helpful for a better understanding of the mechanisms underlying VPA-induced hepatic steatosis and may offer novel therapeutic strategies to combat VPA-induced hepatotoxicity.
28366540	DGAT2	offer	novel therapeutic strategies to combat VPA-induced hepatotoxicity	Overall, VPA-triggered over-regulation of CD36 and DGAT2 could be helpful for a better understanding of the mechanisms underlying VPA-induced hepatic steatosis and may offer novel therapeutic strategies to combat VPA-induced hepatotoxicity.
28449683	FK866	promote	liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro	FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN).
28449683	NAMPT	aggravate	the HFD- or oleic acid-induced hepatic steatosis	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	Nicotinamide	aggravate	the HFD- or oleic acid-induced hepatic steatosis	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NMN	aggravate	the HFD- or oleic acid-induced hepatic steatosis	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NAD	aggravate	the HFD- or oleic acid-induced hepatic steatosis	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	Nicotinamide mononucleotide	aggravate	the HFD- or oleic acid-induced hepatic steatosis	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NAMPT	suppress	Sirt1-mediated signaling pathway	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	Nicotinamide	suppress	Sirt1-mediated signaling pathway	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NMN	suppress	Sirt1-mediated signaling pathway	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NAD	suppress	Sirt1-mediated signaling pathway	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	Nicotinamide mononucleotide	suppress	Sirt1-mediated signaling pathway	Nicotinamide mononucleotide (NMN) and NAD Our results demonstrated that inhibition of NAMPT aggravated the HFD- or oleic acid-induced hepatic steatosis through suppressing Sirt1-mediated signaling pathway.
28449683	NAMPT	reduce	the production of NAD	On the one hand, the inhibition of NAMPT reduced the production of NAD
28465000	aspartame	induce	hyperglycemia and hypertriacylglycerolemia	Subchronic intake of soft drink or aspartame substantially induced hyperglycemia and hypertriacylglycerolemia, as represented by increased serum glucose, triacylglycerol, low-density lipoprotein and very low-density lipoprotein cholesterol, with obvious visceral fatty deposition.
28465000	adiponectin	activate	receptor-γ (PPAR-γ) expression	These metabolic syndromes were associated with the up-regulation of leptin and down-regulation of adiponectin and peroxisome proliferator activated receptor-γ (PPAR-γ) expression.
28777337	Tunicamycin	develop	an anti-cancer drug	Tunicamycin, a pharmacological ER stress inducer, is used to develop an anti-cancer drug.
28777337	ER	develop	an anti-cancer drug	Tunicamycin, a pharmacological ER stress inducer, is used to develop an anti-cancer drug.
28777337	Tunicamycin	induce	a yellowish color and ER stress, as well as	Tunicamycin significantly induced hepatic a yellowish color and ER stress, as well as increasing serum levels of aspartate transaminase and alanine transaminase.
28777337	Tunicamycin	increase	serum levels of aspartate transaminase and alanine transaminase	Tunicamycin significantly induced hepatic a yellowish color and ER stress, as well as increasing serum levels of aspartate transaminase and alanine transaminase.
28777337	tunicamycin	increase	hepatic triglyceride content	Besides, tunicamycin remarkably increased hepatic triglyceride content and suppressed the expression of apolipoprotein B100.
28777337	tunicamycin	suppress	the expression of apolipoprotein B100	Besides, tunicamycin remarkably increased hepatic triglyceride content and suppressed the expression of apolipoprotein B100.
28777337	Tunicamycin	alter	hepatic energy homeostasis	Tunicamycin alters hepatic energy homeostasis by increasing triglyceride accumulation and decreasing glycogen content.
28777337	Tunicamycin	increase	triglyceride accumulation	Tunicamycin alters hepatic energy homeostasis by increasing triglyceride accumulation and decreasing glycogen content.
28777337	Tunicamycin	decrease	glycogen content	Tunicamycin alters hepatic energy homeostasis by increasing triglyceride accumulation and decreasing glycogen content.
28803762	Alcohol	reverse	this disease	Alcohol is a major cause of liver injury, and there are currently no ideal pharmacological reagents that can prevent or reverse this disease.
28803762	Apigenin	increase	the expression of hepatic peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 proteins	Apigenin pretreatment could increase the expression of hepatic peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 proteins, and decrease the expression of hepatic sterol regulatory element binding protein-1c, fatty acid synthase, and diacylglycerol acyltransferase proteins.
28803762	Apigenin	decrease	the expression of hepatic sterol regulatory element binding protein-1c, fatty acid synthase, and diacylglycerol acyltransferase proteins	Apigenin pretreatment could increase the expression of hepatic peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 proteins, and decrease the expression of hepatic sterol regulatory element binding protein-1c, fatty acid synthase, and diacylglycerol acyltransferase proteins.
28803762	apigenin	exert	a protective effect	These findings demonstrated that apigenin might exert a protective effect on alcohol-induced liver injury, and its mechanisms might be related to the regulations of hepatic CYP2E1-mediated oxidative stress and PPARα-mediated lipogenic gene expression.
28933423	omega-3 PUFA	ameliorate	Hcy-induced hepatic steatosis	Omega-3 PUFA was simultaneously administered in HHcy mice through chow diet containing 3.3% omega-3 PUFA supplement for 6 weeks, which significantly ameliorated Hcy-induced hepatic steatosis.
28933423	ceramide	ameliorate	hepatic lipid accumulation	Furthermore, downregulation of ceramide levels through omega-3 PUFA supplementation ameliorates hepatic lipid accumulation.
28933423	omega-3 PUFA	ameliorate	hepatic lipid accumulation	Furthermore, downregulation of ceramide levels through omega-3 PUFA supplementation ameliorates hepatic lipid accumulation.
28962527	Amiodarone	cause	liver steatosis	Amiodarone is a commonly used antiarrhythmic drug and can cause liver steatosis.
28962527	Amiodarone	reduce	intracellular ATP and Ca2	Amiodarone directly reduced intracellular ATP and Ca2+ in hepatocytes invitro, inducing ER stress and lipid accumulation.
28962527	Amiodarone	induce	ER stress and lipid accumulation	Amiodarone directly reduced intracellular ATP and Ca2+ in hepatocytes invitro, inducing ER stress and lipid accumulation.
28962527	amiodarone	increase	hepatic mRNA expression of lipid droplet proteins, particularly Cidea and Cidec, in WT, but	Rather, amiodarone strongly increased hepatic mRNA expression of lipid droplet proteins, particularly Cidea and Cidec, in WT, but less so in Ddit3-/- mice, suggesting a link between ER stress and increased triglyceride storage.
28962527	amiodarone	suggest	a link between ER stress	Rather, amiodarone strongly increased hepatic mRNA expression of lipid droplet proteins, particularly Cidea and Cidec, in WT, but less so in Ddit3-/- mice, suggesting a link between ER stress and increased triglyceride storage.
28962527	amiodarone	increase	triglyceride storage	Rather, amiodarone strongly increased hepatic mRNA expression of lipid droplet proteins, particularly Cidea and Cidec, in WT, but less so in Ddit3-/- mice, suggesting a link between ER stress and increased triglyceride storage.
28962527	insulin	attenuate	amiodarone-induced phosphorylation of hormone sensitive lipase (HSL) in WT	Moreover, while insulin attenuated amiodarone-induced phosphorylation of hormone sensitive lipase (HSL) in WT, it did not affect pHSL in Ddit3-/-, indicating increased lipolysis and therefore reduced lipid accumulation in these mice.
28962527	ER	reduce	lipid accumulation	Finally, ER stress attenuation using 2 different pharmacological chaperones reduced lipid accumulation, accompanied by reduced mRNA expression of Cidec.
28962527	ER	drive	liver steatosis	In conclusion, amiodarone-induced ER stress drives liver steatosis and may be considered for therapeutic targeting.
28987868	Protein kinase B	play	important roles in the regulation of lipid homeostasis, and impairment of Akt activity has been demonstrated to be involved in the development of non-alcoholic fatty liver disease (NAFLD)	Protein kinase B (PKB/Akt) plays important roles in the regulation of lipid homeostasis, and impairment of Akt activity has been demonstrated to be involved in the development of non-alcoholic fatty liver disease (NAFLD).
28987868	PKB/Akt	play	important roles in the regulation of lipid homeostasis, and impairment of Akt activity has been demonstrated to be involved in the development of non-alcoholic fatty liver disease (NAFLD)	Protein kinase B (PKB/Akt) plays important roles in the regulation of lipid homeostasis, and impairment of Akt activity has been demonstrated to be involved in the development of non-alcoholic fatty liver disease (NAFLD).
28987868	cytochrome P4502E1	play	causal roles	Previous studies suggest that cytochrome P4502E1 (CYP2E1) plays causal roles in the pathogenesis of alcoholic fatty liver (AFL).
28987868	CYP2E1	play	causal roles	Previous studies suggest that cytochrome P4502E1 (CYP2E1) plays causal roles in the pathogenesis of alcoholic fatty liver (AFL).
28987868	ethanol	have	no effects on the protein levels of phosphatidylinositol 3 kinase (PI3K) and phosphatase and tensin homologue deleted on chromosome ten (PTEN)	Chronic ethanol exposure had no effects on the protein levels of phosphatidylinositol 3 kinase (PI3K) and phosphatase and tensin homologue deleted on chromosome ten (PTEN), and led to a slight decrease of phosphoinositide-dependent protein kinase 1 (PDK-1) protein level.
28987868	N-acetyl-L-cysteine	attenuate	chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308	Interestingly, N-acetyl-L-cysteine (NAC) significantly attenuated chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308.
28987868	NAC	attenuate	chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308	Interestingly, N-acetyl-L-cysteine (NAC) significantly attenuated chronic ethanol-induced hepatic fat accumulation and the decline of Akt phosphorylation at Thr308.
28987868	Akt	alleviate	chronic ethanol-induced fatty liver	Lastly, pharmacological activation of Akt by insulin-like growth factor-1 (IGF-1) significantly alleviated chronic ethanol-induced fatty liver in mice.
28987868	insulin-like growth factor-1	alleviate	chronic ethanol-induced fatty liver	Lastly, pharmacological activation of Akt by insulin-like growth factor-1 (IGF-1) significantly alleviated chronic ethanol-induced fatty liver in mice.
28987868	IGF-1	alleviate	chronic ethanol-induced fatty liver	Lastly, pharmacological activation of Akt by insulin-like growth factor-1 (IGF-1) significantly alleviated chronic ethanol-induced fatty liver in mice.
29126901	LXR activator	induced	lipid accumulation and docosahexaenoic acid (DHA; a representative n-3 PUFA)	T0901317 (a specific LXR activator) induced lipid accumulation and docosahexaenoic acid (DHA; a representative n-3 PUFA) inhibited lipid accumulation.
29126901	LXR activator	inhibit	lipid accumulation	T0901317 (a specific LXR activator) induced lipid accumulation and docosahexaenoic acid (DHA; a representative n-3 PUFA) inhibited lipid accumulation.
29126901	DHA	inhibit	T0901317-induced lipid accumulation in primary hepatocytes from wild type mice, but not in those from FFA4 deficient mice	Furthermore, DHA inhibited T0901317-induced lipid accumulation in primary hepatocytes from wild type mice, but not in those from FFA4 deficient mice.
29169220	HepG2 cells	induce	lipogenesis and accumulation of intracellular lipid contents	HepG2 cells were incubated with palmitic acid (PA) for 24 h to induce lipogenesis and accumulation of intracellular lipid contents.
29169220	HepG2 cells	increase	the expression of SREBP-1	Treatment of HepG2 cells with PA combined with genistein or estrogen significantly increased the expression of SREBP-1.
29169220	PA	increase	the expression of SREBP-1	Treatment of HepG2 cells with PA combined with genistein or estrogen significantly increased the expression of SREBP-1.
29169220	estrogen	increase	the expression of SREBP-1	Treatment of HepG2 cells with PA combined with genistein or estrogen significantly increased the expression of SREBP-1.
29169220	genistein	increase	the expression of SREBP-1	Treatment of HepG2 cells with PA combined with genistein or estrogen significantly increased the expression of SREBP-1.
29404450	intracellular	play	a key role	It has become clear that autophagy, a catabolic process of intracellular degradation and recycling, plays a key role in hepatic lipid metabolism.
29404450	hepatocytes	contain	juxtanuclear lysosomes that exhibited impaired motility	Interestingly, hepatocytes isolated from these ethanol-fed rats contained juxtanuclear lysosomes that exhibited impaired motility.
29404450	juxtanuclear lysosomes	exhibit	impaired motility	Interestingly, hepatocytes isolated from these ethanol-fed rats contained juxtanuclear lysosomes that exhibited impaired motility.
29457836	alcohol	cause	hepatic lipid accumulation	However, how chronic alcohol consumption causes hepatic lipid accumulation remains elusive.
29457836	rapamycin complex 1	play	a causal role	The present study demonstrates that activation of the mechanistic target of rapamycin complex 1 (mTORC1) plays a causal role in alcoholic steatosis, inflammation, and liver injury.
29457836	rapamycin	play	a causal role	The present study demonstrates that activation of the mechanistic target of rapamycin complex 1 (mTORC1) plays a causal role in alcoholic steatosis, inflammation, and liver injury.
29457836	hepatic DEPTOR	suppress	mTORC1 signaling	Conversely, adenoviral overexpression of hepatic DEPTOR suppressed mTORC1 signaling and ameliorated alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury.
29457836	hepatic DEPTOR	ameliorate	alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury	Conversely, adenoviral overexpression of hepatic DEPTOR suppressed mTORC1 signaling and ameliorated alcoholic hepatosteatosis, inflammation, and acute-on-chronic liver injury.
29457836	mTORC1	attenuate	alcohol-induced cytoplasmic accumulation of the lipogenic regulator lipin 1	DEPTOR-dependent inhibition of mTORC1 also attenuated alcohol-induced cytoplasmic accumulation of the lipogenic regulator lipin 1 and prevented alcohol-mediated inhibition of fatty acid oxidation.
29457836	mTORC1	prevent	alcohol-mediated inhibition of fatty acid oxidation	DEPTOR-dependent inhibition of mTORC1 also attenuated alcohol-induced cytoplasmic accumulation of the lipogenic regulator lipin 1 and prevented alcohol-mediated inhibition of fatty acid oxidation.
29457836	rapamycin	alleviate	the ability of alcohol to up-regulate lipogenesis	Pharmacological intervention with rapamycin alleviated the ability of alcohol to up-regulate lipogenesis, to down-regulate fatty acid oxidation, and to induce steatogenic phenotypes.
29457836	rapamycin	down-regulate	fatty acid oxidation	Pharmacological intervention with rapamycin alleviated the ability of alcohol to up-regulate lipogenesis, to down-regulate fatty acid oxidation, and to induce steatogenic phenotypes.
29457836	rapamycin	induce	steatogenic phenotypes	Pharmacological intervention with rapamycin alleviated the ability of alcohol to up-regulate lipogenesis, to down-regulate fatty acid oxidation, and to induce steatogenic phenotypes.
29457836	hepatocyte-specific	disrupt	DEPTOR function	Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice.
29457836	SIRT1	disrupt	DEPTOR function	Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice.
29457836	hepatocyte-specific	enhance	mTORC1 activity	Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice.
29457836	SIRT1	enhance	mTORC1 activity	Furthermore, hepatocyte-specific deletion of SIRT1 disrupted DEPTOR function, enhanced mTORC1 activity, and exacerbated alcoholic fatty liver, inflammation, and liver injury in mice.
29526820	benzbromarone	induce	hepatic toxicity in patients	As a widely used anti-gout drug, benzbromarone has been found to induce hepatic toxicity in patients during clinical treatment.
29526820	benzbromarone	aggravate	hepatic steatosis in both obese db/db mice and high fat diet (HFD)-induced obese (DIO) mouse models	In this study, we found that benzbromarone significantly aggravated hepatic steatosis in both obese db/db mice and high fat diet (HFD)-induced obese (DIO) mouse models.
29526820	benzbromarone	have	less effect on the liver of lean mice	However, benzbromarone had less effect on the liver of lean mice.
29526820	benzbromarone	promote	intracellular lipid accumulation under high free fatty acids (FFAs) conditions	In accordance with the in vivo results, an in vitro experiment using human hepatoma HepG2 cells also confirmed that benzbromarone promoted intracellular lipid accumulation under high free fatty acids (FFAs) conditions by regulating the expression of lipid metabolism genes.
29526820	benzbromarone	regulate	the expression of lipid metabolism genes	In accordance with the in vivo results, an in vitro experiment using human hepatoma HepG2 cells also confirmed that benzbromarone promoted intracellular lipid accumulation under high free fatty acids (FFAs) conditions by regulating the expression of lipid metabolism genes.
29526820	benzbromarone	increase	cell apoptosis in HepG2 cells	Importantly, prolonged treatment of benzbromarone significantly increased cell apoptosis in HepG2 cells in the presence of high FFAs.
29526820	benzbromarone	aggravate	hepatic steatosis in obese individuals,	This study demonstrated that benzbromarone aggravated hepatic steatosis in obese individuals, which could subsequently contribute to hepatic cell injury, suggesting a novel toxicological mechanism in benzbromarone-induced hepatotoxicity.
29526820	benzbromarone	suggest	a novel toxicological mechanism in benzbromarone-induced hepatotoxicity	This study demonstrated that benzbromarone aggravated hepatic steatosis in obese individuals, which could subsequently contribute to hepatic cell injury, suggesting a novel toxicological mechanism in benzbromarone-induced hepatotoxicity.
29529605	AMPKα	increase	the expression and transcriptional activity of peroxisome proliferator-activated receptor α	Acetic acid treatment increased AMPKα phosphorylation, which subsequently increased the expression and transcriptional activity of peroxisome proliferator-activated receptor α and upregulated the expression of lipid oxidation genes.
29529605	AMPKα	upregulate	the expression of lipid oxidation genes	Acetic acid treatment increased AMPKα phosphorylation, which subsequently increased the expression and transcriptional activity of peroxisome proliferator-activated receptor α and upregulated the expression of lipid oxidation genes.
29529605	element-binding protein 1c	reduce	the expression of lipogenic genes	Furthermore, elevated AMPKα phosphorylation reduced the expression and transcriptional activity of the sterol regulatory element-binding protein 1c, which reduced the expression of lipogenic genes, thereby decreasing lipid biosynthesis in BRL-3A cells.
29529605	acetic acid	activate	the AMPKα signalling pathway	These results indicate that acetic acid activates the AMPKα signalling pathway, leading to increased lipid oxidation and decreased lipid synthesis in BRL-3A cells, thereby reducing liver fat accumulation in vitro.
29529605	acetic acid	decrease	lipid synthesis in BRL-3A cells	These results indicate that acetic acid activates the AMPKα signalling pathway, leading to increased lipid oxidation and decreased lipid synthesis in BRL-3A cells, thereby reducing liver fat accumulation in vitro.
29529605	acetic acid	reduce	liver fat accumulation	These results indicate that acetic acid activates the AMPKα signalling pathway, leading to increased lipid oxidation and decreased lipid synthesis in BRL-3A cells, thereby reducing liver fat accumulation in vitro.
29587622	Diacylglycerol acyltransferase 1	catalyze	the final step in triglyceride synthesis	Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in triglyceride synthesis.
29587622	Diacylglycerol	catalyze	the final step in triglyceride synthesis	Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in triglyceride synthesis.
29597210	Saturated fatty acid palmitate	stimulate	lipid accumulation and apoptosis in hepatocytes	Saturated fatty acid palmitate stimulates lipid accumulation and apoptosis in hepatocytes.
29597210	Palmitate	induce	lipid accumulation and mRNA expression of lipogenic genes such as SREBP1c and SCD1	Palmitate induced lipid accumulation and mRNA expression of lipogenic genes such as SREBP1c and SCD1.
29597210	palmitate	stimulate	caspase-3 activity	Furthermore, palmitate stimulated caspase-3 activity and decreased cell viability in the absence of BO.
29597210	palmitate	decrease	cell viability	Furthermore, palmitate stimulated caspase-3 activity and decreased cell viability in the absence of BO.
29597210	AMP-activated protein kinase	abolish	the effects of BO	AMP-activated protein kinase inhibitors abolished the effects of BO.
29597210	BO	attenuate	palmitate-induced hepatic steatosis and apoptosis	In conclusion, BO attenuated palmitate-induced hepatic steatosis and apoptosis through AMPK-mediated suppression of JNK signaling.
29625129	miR-378	impair	FAO	Overexpression of miR-378 impaired FAO and promoted lipid accumulation in murine hepatoma Hepa1-6 cells.
29625129	miR-378	promote	lipid accumulation in murine hepatoma Hepa1-6 cells	Overexpression of miR-378 impaired FAO and promoted lipid accumulation in murine hepatoma Hepa1-6 cells.
29625129	miR-378	improve	FAO	In contrast, knockdown of miR-378 using its ASO (anti-sense oligo) improved FAO and reduced intracellular lipid content in Hepa1-6 cells.
29625129	miR-378	reduce	intracellular lipid content in Hepa1-6 cells	In contrast, knockdown of miR-378 using its ASO (anti-sense oligo) improved FAO and reduced intracellular lipid content in Hepa1-6 cells.
29625129	Liver-specific	impair	FAO, which subsequently promoted the development of hepatosteatosis	Liver-specific expression of miR-378 impaired FAO, which subsequently promoted the development of hepatosteatosis.
29625129	miR-378	impair	FAO, which subsequently promoted the development of hepatosteatosis	Liver-specific expression of miR-378 impaired FAO, which subsequently promoted the development of hepatosteatosis.
29625129	miR-378	promote	the development of hepatosteatosis	Liver-specific expression of miR-378 impaired FAO, which subsequently promoted the development of hepatosteatosis.
29625129	Nrf1	offset	the effects of miR-378-ASO	Additional knockdown of up-regulated Nrf1 offset the effects of miR-378-ASO, suggesting that Nrf1 mediated the inhibitory effect of miR-378-ASO on hepatosteatosis.
29625129	Nrf1	mediate	the inhibitory effect of miR-378-ASO on hepatosteatosis	Additional knockdown of up-regulated Nrf1 offset the effects of miR-378-ASO, suggesting that Nrf1 mediated the inhibitory effect of miR-378-ASO on hepatosteatosis.
29625129	Nrf1	mediate	the inhibitory effect of miR-378-ASO on hepatosteatosis	Additional knockdown of up-regulated Nrf1 offset the effects of miR-378-ASO, suggesting that Nrf1 mediated the inhibitory effect of miR-378-ASO on hepatosteatosis.
29625129	Nrf1	promote	the pathogenesis of hepatosteatosis	These findings identified a negative feedback loop between miR-378 and Nrf1 that promotes the pathogenesis of hepatosteatosis, and suggests the use of miR-378 as a potential therapeutic target for NAFLD.
29630881	aldose reductase	ameliorate	alcoholic hepatic steatosis	Previously we demonstrated that aldose reductase (AR) inhibitor ameliorated alcoholic hepatic steatosis.
29630881	AR	improve	alcoholic hepatic steatosis	To clarify the mechanism whereby AR inhibitor improves alcoholic hepatic steatosis, herein we investigated the effect of AR inhibitor on hepatic metabolism in mice fed a Lieber-DeCarli liquid diet with 5% ethanol.
29630881	AR	feed	a Lieber-DeCarli liquid diet	To clarify the mechanism whereby AR inhibitor improves alcoholic hepatic steatosis, herein we investigated the effect of AR inhibitor on hepatic metabolism in mice fed a Lieber-DeCarli liquid diet with 5% ethanol.
29630881	AR	affect	carbohydrates and peptides	Nontargeted metabolomics showed carbohydrates and lipids were characteristic categories in ethanol diet-fed mice with or without AR inhibitor treatment, whereas AR inhibitor mainly affected carbohydrates and peptides.
29630881	AR	impair	galactose metabolism	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	galactose	impair	galactose metabolism	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	fatty acid	impair	galactose metabolism	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	AR	perturb	fatty acid biosynthesis	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	galactose	perturb	fatty acid biosynthesis	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	fatty acid	perturb	fatty acid biosynthesis	Ethanol-induced galactose metabolism and fatty acid biosynthesis are important for the induction of hepatic steatosis, while AR inhibitor impaired galactose metabolism without perturbing fatty acid biosynthesis.
29630881	AR	suppress	ethanol-activated galactose metabolism and saturated fatty acid biosynthesis	In parallel with successful treatment of steatosis, AR inhibitor suppressed ethanol-activated galactose metabolism and saturated fatty acid biosynthesis.
29630881	sorbitol	augment	ethanol-induced steatosis and stearic acid	In vitro analysis confirmed that exogenous addition of sorbitol augmented ethanol-induced steatosis and stearic acid.
29704577	lipids	modify	energy metabolism, hepatic structure and function	Remains unknown if dietary lipids and anabolic steroids (AS) can interact to modify energy metabolism, hepatic structure and function.
29704577	steroids	modify	energy metabolism, hepatic structure and function	Remains unknown if dietary lipids and anabolic steroids (AS) can interact to modify energy metabolism, hepatic structure and function.
29704577	AS	reduce	plasma HDL cholesterol levels	When combined with a HFD, AS reduced plasma HDL cholesterol levels.
29782848	alcohol	affect	these processes	We investigated the mechanisms by which alcohol consumption affects these processes by evaluating the functions of transcription factor EB (TFEB), which regulates lysosomal biogenesis.
29782848	TFEB	regulate	lysosomal biogenesis	We investigated the mechanisms by which alcohol consumption affects these processes by evaluating the functions of transcription factor EB (TFEB), which regulates lysosomal biogenesis.
29782848	alcohol	evaluate	the functions of transcription factor EB (TFEB), which regulates lysosomal biogenesis	We investigated the mechanisms by which alcohol consumption affects these processes by evaluating the functions of transcription factor EB (TFEB), which regulates lysosomal biogenesis.
29782848	liver-specific	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFEB	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tefb	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tfe3	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFEB	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFE3	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tfeb Liver tissues	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	ethanol	have	lower levels of total and nuclear TFEB	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	hepatocytes	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	liver-specific	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFEB	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tefb	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tfe3	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFEB	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	TFE3	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Tfeb Liver tissues	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	ethanol	decrease	lysosome biogenesis and autophagy	We performed studies with GFP-LC3 mice, mice with liver-specific deletion of TFEB, mice with disruption of the transcription factor E3 gene (TFE3-knockout mice), mice with disruption of the Tefb and Tfe3 genes (TFEB and TFE3 double-knockout mice), and Tfeb Liver tissues from mice on the ethanol diet had lower levels of total and nuclear TFEB compared with control mice, and hepatocytes had decreased lysosome biogenesis and autophagy.
29782848	Hepatocytes	increase	translocation of mTOR into lysosomes	Hepatocytes from mice on the ethanol diet had increased translocation of mTOR into lysosomes, resulting in increased mTOR activation.
29782848	ethanol	increase	translocation of mTOR into lysosomes	Hepatocytes from mice on the ethanol diet had increased translocation of mTOR into lysosomes, resulting in increased mTOR activation.
29782848	torin-1	increase	liver levels of TFEB	Administration of torin-1 increased liver levels of TFEB and decreased steatosis and liver injury induced by ethanol.
29782848	torin-1	decrease	steatosis and liver injury induced by ethanol	Administration of torin-1 increased liver levels of TFEB and decreased steatosis and liver injury induced by ethanol.
29782848	TFEB	develop	less severe ethanol-induced liver injury	Mice that overexpressed TFEB in the liver developed less severe ethanol-induced liver injury and had increased lysosomal biogenesis and mitochondrial bioenergetics compared with mice carrying a control vector.
29782848	TFEB	increase	lysosomal biogenesis and mitochondrial bioenergetics	Mice that overexpressed TFEB in the liver developed less severe ethanol-induced liver injury and had increased lysosomal biogenesis and mitochondrial bioenergetics compared with mice carrying a control vector.
29782848	TFEB	develop	more severe liver injury	Mice with knockdown of TFEB and TFEB-TFE3 double-knockout mice developed more severe liver injury in response to the ethanol diet than control mice.
29782848	TFEB-TFE3	develop	more severe liver injury	Mice with knockdown of TFEB and TFEB-TFE3 double-knockout mice developed more severe liver injury in response to the ethanol diet than control mice.
29782848	Liver tissues	have	 lower nuclear levels of TFEB than control tissues	Liver tissues from patients with alcohol-induced hepatitis had lower nuclear levels of TFEB than control tissues.
29782848	ethanol	decrease	hepatic expression of TFEB, which is required for lysosomal biogenesis and autophagy	We found that ethanol feeding plus an acute binge decreased hepatic expression of TFEB, which is required for lysosomal biogenesis and autophagy.
29782848	mTOR	protect	the liver	Strategies to block mTOR activity or increase levels of TFEB might be developed to protect the liver from ethanol-induced damage.
29782848	TFEB	protect	the liver	Strategies to block mTOR activity or increase levels of TFEB might be developed to protect the liver from ethanol-induced damage.
29934713	Lipin-1	perform	dual function	Lipin-1 performs dual function during lipid metabolism, i.e., it functions as a transcriptional coactivator and as a phosphatidate phosphatase during triglyceride biosynthesis.
29934713	exendin-4	prevent	endoplasmic reticulum (ER) stress-induced hepatic steatosis	We investigated whether exendin-4 prevented endoplasmic reticulum (ER) stress-induced hepatic steatosis and whether the protective effects of exendin-4 were associated with lipin-1 signaling.
29934713	Exendin-4	decrease	the expression of ER stress markers	Exendin-4 decreased the expression of ER stress markers phosphorylated PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α), and glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA and increased the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells.
29934713	Exendin-4	decrease	glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA	Exendin-4 decreased the expression of ER stress markers phosphorylated PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α), and glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA and increased the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells.
29934713	Exendin-4	phosphorylate	PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α)	Exendin-4 decreased the expression of ER stress markers phosphorylated PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α), and glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA and increased the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells.
29934713	Exendin-4	increase	the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells	Exendin-4 decreased the expression of ER stress markers phosphorylated PKR like ER kinase (PERK), phosphorylated inositol-requiring enzyme 1 alpha (IRE1α), and glucose-regulated protein 78 kDa (GRP78) proteins and spliced X-box binding protein 1 (XBP-1s) mRNA and increased the expression of genes encoding lipolytic enzymes hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) and VLDL assembly-associated proteins microsomal triglyceride transfer protein (MTP) and apolipoprotein B (APOB) in tunicamycin-pretreated cells.
29934713	exendin-4	decrease	lipin-1β/α ratio	Moreover, exendin-4 significantly decreased lipin-1β/α ratio by increasing SFRP10 and increased lipin-1 nuclear localization.
29934713	exendin-4	increase	SFRP10	Moreover, exendin-4 significantly decreased lipin-1β/α ratio by increasing SFRP10 and increased lipin-1 nuclear localization.
29934713	exendin-4	increase	lipin-1 nuclear localization	Moreover, exendin-4 significantly decreased lipin-1β/α ratio by increasing SFRP10 and increased lipin-1 nuclear localization.
29934713	exendin-4	improve	ER stress-induced hepatic lipid accumulation	These data suggest that exendin-4 improves ER stress-induced hepatic lipid accumulation by increasing lipolysis and VLDL assembly, which is partially mediated by the regulation of lipin-1 signaling.
29934713	exendin-4	increase	lipolysis and VLDL assembly	These data suggest that exendin-4 improves ER stress-induced hepatic lipid accumulation by increasing lipolysis and VLDL assembly, which is partially mediated by the regulation of lipin-1 signaling.
30138652	Nanoparticle	promote	hepatic steatosis	Nanoparticle (NP) exposure might promote hepatic steatosis, but relatively few studies investigated the influence of multi-walled carbon nanotubes (MWCNTs) on lipid accumulation in hepatocytes in vitro.
30138652	Nanoparticle	investigate	the influence of multi-walled carbon nanotubes (MWCNTs) on lipid accumulation in hepatocytes	Nanoparticle (NP) exposure might promote hepatic steatosis, but relatively few studies investigated the influence of multi-walled carbon nanotubes (MWCNTs) on lipid accumulation in hepatocytes in vitro.
30138652	MWCNTs	accompany	cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production	Pristine (XFM19) and carboxylated MWCNTs (XFM21) were internalized, accompanying cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production.
30138652	carboxylated MWCNTs	accompany	cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production	Pristine (XFM19) and carboxylated MWCNTs (XFM21) were internalized, accompanying cytotoxicity, lysosomal destabilization, and intracellular reactive oxygen species (ROS) production.
30214048	JMJD2B	stimulate	the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation	Overexpression of JMJD2B using adenovirus in HepG2 cells stimulated the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation, resulting in increased intracellular triglyceride (TG) accumulation.
30214048	HepG2 cells	stimulate	the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation	Overexpression of JMJD2B using adenovirus in HepG2 cells stimulated the expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its steatosis target genes associated with fatty acid uptake and lipid droplet formation, resulting in increased intracellular triglyceride (TG) accumulation.
30214048	JMJD2B	feed	a HFD, which was accompanied with increased expression of hepatic PPARγ2 and its steatosis target genes	Furthermore, exogeneous expression of JMJD2B using adenovirus in mice resulted in hepatic steatosis when fed a HFD, which was accompanied with increased expression of hepatic PPARγ2 and its steatosis target genes.
30248338	hepatocyte VDR	set	steatosis	However, how hepatocyte VDR is involved in setting up steatosis remains unclear.
30248338	ANGPTL8	attenuate	free fatty acids-induced triglyceride accumulation in these cells	Additionally, free fatty acids and insulin were able to up-regulate both VDR and ANGPTL8 mRNA in human hepatocytes, whereas ANGPTL8 gene knockdown attenuated free fatty acids-induced triglyceride accumulation in these cells.
30248338	fatty acids	up-regulate	both VDR and ANGPTL8 mRNA	Additionally, free fatty acids and insulin were able to up-regulate both VDR and ANGPTL8 mRNA in human hepatocytes, whereas ANGPTL8 gene knockdown attenuated free fatty acids-induced triglyceride accumulation in these cells.
30248338	insulin	up-regulate	both VDR and ANGPTL8 mRNA	Additionally, free fatty acids and insulin were able to up-regulate both VDR and ANGPTL8 mRNA in human hepatocytes, whereas ANGPTL8 gene knockdown attenuated free fatty acids-induced triglyceride accumulation in these cells.
30248338	VDR	up-regulate	ANGPTL8 expression	In conclusion, activated VDR up-regulates ANGPTL8 expression, contributing to triglyceride accumulation in human hepatocytes.
30248338	hepatic ANGPTL8	play	a key role	Moreover, hepatic ANGPTL8 mRNA positively correlates with VDR mRNA content and the grade of steatosis in NAFL patients, suggesting that this novel pathway may play a key role in the pathogenesis of hepatosteatosis.
30452912	Doxorubicin	disturb	the lipid metabolism	Doxorubicin would disturb the lipid metabolism both in adipose and liver.
30452912	doxorubicin	impede	lipogenesis and elevated lipolysis	Here we projected that doxorubicin would impede lipogenesis and elevated lipolysis in adipose tissue would elevate the circulatory lipid profile and leads to insulin resistance.
30452912	Doxorubicin	impair	the lipogenesis through PPARγ	Doxorubicin impairs the lipogenesis through PPARγ and augments lipolysis and fatty acid oxidation through ATGL and PPARα in adipose tissue.
30452912	Doxorubicin	augment	lipolysis and fatty acid oxidation through ATGL and PPARα	Doxorubicin impairs the lipogenesis through PPARγ and augments lipolysis and fatty acid oxidation through ATGL and PPARα in adipose tissue.
30452912	Apo B	develop	insulin resistance and hepatic steatosis condition	Increased fatty acid level by adipose tissue in circulation would translocate into the liver and dysregulates AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition.
30452912	fatty acid	dysregulate	AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition	Increased fatty acid level by adipose tissue in circulation would translocate into the liver and dysregulates AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition.
30452912	adipose tissue	dysregulate	AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition	Increased fatty acid level by adipose tissue in circulation would translocate into the liver and dysregulates AHR, PXR, PPARγ, ATGL and Apo B,which further develop insulin resistance and hepatic steatosis condition.
30557836	Dipeptidyl peptidase-4	exert	beneficial effects against insulin resistance (IR) and type 2 diabetes	Dipeptidyl peptidase-4 (DPP-4) inhibition has been shown to exert beneficial effects against insulin resistance (IR) and type 2 diabetes.
30557836	DPP-4	ameliorate	COC-induced glucose dysregulation and hepatic triglyceride (TG) accumulation through adenosine deaminase (ADA) /xanthine oxidase (XO) /uric acid-dependent pathway	We therefore, hypothesized that DPP-4 inhibition ameliorates COC-induced glucose dysregulation and hepatic triglyceride (TG) accumulation through adenosine deaminase (ADA) /xanthine oxidase (XO) /uric acid-dependent pathway.
30557836	COC	result	in increased plasma and hepatic TG, TG/HDL-cholesterol ratio, malondialdehyde, uric acid (plasma; 25.2 ± 0.6 mg/dl; hepatic 128.9 ± 8.0 mg/100 mg tissue), lactate dehydrogenase, DPP-4, ADA and XO (plasma;10.5 ± 1.1 U/L; hepatic 21.2 ± 1.4 U/g protein) activities	COC treatment also resulted in increased plasma and hepatic TG, TG/HDL-cholesterol ratio, malondialdehyde, uric acid (plasma; 25.2 ± 0.6 mg/dl; hepatic 128.9 ± 8.0 mg/100 mg tissue), lactate dehydrogenase, DPP-4, ADA and XO (plasma;10.5 ± 1.1 U/L; hepatic 21.2 ± 1.4 U/g protein) activities.
30557836	DPP-4	ameliorate	these alterations induced by COC treatment through suppression of uric acid (plasma; 15.1 ± 1.0 mg/dl, hepatic; 75.6 ± 5.0 mg/100 mg tissue), XO (plasma;	However, DPP-4 inhibition significantly ameliorated these alterations induced by COC treatment through suppression of uric acid (plasma; 15.1 ± 1.0 mg/dl, hepatic; 75.6 ± 5.0 mg/100 mg tissue), XO (plasma; 4.1 ± 0.9 U/L, hepatic; 8.7 ± 0.4 U/g protein), ADA and DPP-4 activities suggesting their involvement in glucose dysregulation and hepatic TG accumulation induced by COC treatment.
30557836	DPP-4	ameliorate	4.1 ± 0.9 U/L, hepatic; 8.7 ± 0.4 U/g protein), ADA and DPP-4 activities suggesting their involvement in glucose dysregulation and hepatic TG accumulation induced by COC treatment	However, DPP-4 inhibition significantly ameliorated these alterations induced by COC treatment through suppression of uric acid (plasma; 15.1 ± 1.0 mg/dl, hepatic; 75.6 ± 5.0 mg/100 mg tissue), XO (plasma; 4.1 ± 0.9 U/L, hepatic; 8.7 ± 0.4 U/g protein), ADA and DPP-4 activities suggesting their involvement in glucose dysregulation and hepatic TG accumulation induced by COC treatment.
30562559	p70 ribosomal protein subunit 6 kinase 1	improve	hepatic steatosis	Administration of adenovirus-mediated p70 ribosomal protein subunit 6 kinase 1 (Ad-S6K1) from tail vein improved hepatic steatosis.
30677459	cell	study	the impact of efavirenz on PXR activities and lipid homeostasis	Cell-based reporter assays, primary cell culture, and multiple mouse models including conditional knockout and humanized mice were combined to study the impact of efavirenz on PXR activities and lipid homeostasis in vitro and in vivo.
30677459	efavirenz	activate	PXR	We found that efavirenz is a potent PXR-selective agonist that can efficiently activate PXR and induce its target gene expression in vitro and in vivo.
30677459	efavirenz	induce	its target gene expression	We found that efavirenz is a potent PXR-selective agonist that can efficiently activate PXR and induce its target gene expression in vitro and in vivo.
30677459	hepatic PXR	abolish	these adverse effects	Treatment with efavirenz-induced hypercholesterolemia and hepatic steatosis in mice but deficiency of hepatic PXR abolished these adverse effects.
30677459	PXR	regulate	the expression of several key hepatic lipogenic genes including fatty acid transporter CD36 and cholesterol biosynthesis enzyme squalene epoxidase (SQLE)	Interestingly, efavirenz-mediated PXR activation regulated the expression of several key hepatic lipogenic genes including fatty acid transporter CD36 and cholesterol biosynthesis enzyme squalene epoxidase (SQLE), leading to increased lipid uptake and cholesterol biosynthesis in hepatic cells.
30677459	PXR	exhibit	considerable differences in its pharmacology across species	Since PXR exhibits considerable differences in its pharmacology across species, we also confirmed these findings in PXR-humanized mice and human primary hepatocytes.
30677459	efavirenz	induce	hypercholesterolemia and hepatic steatosis	The widely prescribed antiretroviral drug efavirenz induces hypercholesterolemia and hepatic steatosis by activating PXR signaling.
30677459	efavirenz	activate	PXR signaling	The widely prescribed antiretroviral drug efavirenz induces hypercholesterolemia and hepatic steatosis by activating PXR signaling.
30677459	efavirenz	activate	a unique liver protein called PXR which mediates the adverse effects of efavirenz on lipid levels in mouse models	Here we show that efavirenz can activate a unique liver protein called PXR which mediates the adverse effects of efavirenz on lipid levels in mouse models.
30677459	PXR	mediate	the adverse effects of efavirenz on lipid levels in mouse models	Here we show that efavirenz can activate a unique liver protein called PXR which mediates the adverse effects of efavirenz on lipid levels in mouse models.
30824780	Cell	add	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)	Cell viability was assessed by adding 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).
30824780	Silybin	ameliorate	the harmful BPA-induced effect decreasing glucose uptake and lipid peroxidation	Silybin ameliorates the harmful BPA-induced effect decreasing glucose uptake and lipid peroxidation.
30824780	silybin	activate	the synthesis of vitamin D3 metabolites	Moreover silybin activates the synthesis of vitamin D3 metabolites and prevent the steroid hormones oxidation.
30824780	silybin	prevent	the steroid hormones oxidation	Moreover silybin activates the synthesis of vitamin D3 metabolites and prevent the steroid hormones oxidation.
30880507	Metformin	inhibit	gluconeogenesis and glycogenolysis in hepatocytes	Metformin is an oral hypoglycemic medication which inhibits gluconeogenesis and glycogenolysis in hepatocytes and limits lipid storage in the liver through the inhibition of free fatty acid formation via induction of activated protein kinase activity (AMPK).
30880507	Metformin	limit	lipid storage in the liver	Metformin is an oral hypoglycemic medication which inhibits gluconeogenesis and glycogenolysis in hepatocytes and limits lipid storage in the liver through the inhibition of free fatty acid formation via induction of activated protein kinase activity (AMPK).
30880507	endocannabinoids	modulate	hepatosteatosis	Both endocannabinoids and metformin may modulate hepatosteatosis; therefore, it was interesting to examine whether metformin may affect lipid accumulation in hepatocytes by acting on cannabinoid receptors, CB1 and CB2, in in vitro study.
30880507	metformin	modulate	hepatosteatosis	Both endocannabinoids and metformin may modulate hepatosteatosis; therefore, it was interesting to examine whether metformin may affect lipid accumulation in hepatocytes by acting on cannabinoid receptors, CB1 and CB2, in in vitro study.
30880507	metformin	affect	lipid accumulation in hepatocytes	Both endocannabinoids and metformin may modulate hepatosteatosis; therefore, it was interesting to examine whether metformin may affect lipid accumulation in hepatocytes by acting on cannabinoid receptors, CB1 and CB2, in in vitro study.
30880507	intracellular lipids	use	Oil-Red-O staining	The quantity of intracellular lipids was assessed using Oil-Red-O staining.
30880507	AM1241	treat	Hep3B cells	Selective CB1R agonist, arachidonyl-2-chloromethylamide (ACEA), and CB2R agonist, AM1241 (2-iodo-5-nitrophenyl)-[1-(methylpiperidin-2-ylmethyl)-1 H-indol-3-yl]methanone, were also used to treat Hep3B cells.
30880507	H-indol-3-yl]methanone	treat	Hep3B cells	Selective CB1R agonist, arachidonyl-2-chloromethylamide (ACEA), and CB2R agonist, AM1241 (2-iodo-5-nitrophenyl)-[1-(methylpiperidin-2-ylmethyl)-1 H-indol-3-yl]methanone, were also used to treat Hep3B cells.
30880507	Met	decrease	lipid accumulation in cells treated with OA	In the study, Met decreased lipid accumulation in cells treated with OA and inhibited CB1R agonist-induced lipid accumulation in hepatocytes.
30880507	Met	inhibit	CB1R agonist-induced lipid accumulation in hepatocytes	In the study, Met decreased lipid accumulation in cells treated with OA and inhibited CB1R agonist-induced lipid accumulation in hepatocytes.
30880507	metformin	inhibit	CB1R agonist-stimulated fat accumulation in hepatocytes	The results indicate that metformin may interact with endocannabinoid system in the liver by inhibiting CB1R agonist-stimulated fat accumulation in hepatocytes.
31026768	Vinyl chloride	cause	steatohepatitis	Vinyl chloride (VC), an abundant environmental contaminant causes steatohepatitis at high levels, but is considered safe at lower (i.e., sub-OSHA) levels.
31026768	Mitochondrial	play	key roles	Mitochondrial oxidative injury and subsequent metabolic dysfunction appeared to play key roles in mediating this interaction.
31026768	Mitochondrial	mediate	this interaction	Mitochondrial oxidative injury and subsequent metabolic dysfunction appeared to play key roles in mediating this interaction.
31026768	low-dose	cause	liver injury	As observed previously, low-dose VC did not cause liver injury in control mice; while liver injury caused by HFD was enhanced by VC.
31026768	VC	decrease	hepatic ALDH2 activity of mice	VC decreased hepatic ALDH2 activity of mice fed HFD.
31026768	VC	feed	HFD	VC decreased hepatic ALDH2 activity of mice fed HFD.
31026768	Alda-1	attenuate	oxidative stress, liver injury, and dysmetabolism in mice exposed to HFD+VC under these conditions	Alda-1 attenuated oxidative stress, liver injury, and dysmetabolism in mice exposed to HFD+VC under these conditions.
31026768	Alda-1	suppress	PINK1/PARKIN-mediated mitophagy	Here, Alda-1 suppressed PINK1/PARKIN-mediated mitophagy.
31026768	ALDH2	confer	protection against liver damage under these conditions	The ALDH2 activator Alda-1 conferred protection against liver damage under these conditions, most likely via increasing clearance of aldehydes and preserving mitochondrial respiratory function.
31026768	Alda-1	confer	protection against liver damage under these conditions	The ALDH2 activator Alda-1 conferred protection against liver damage under these conditions, most likely via increasing clearance of aldehydes and preserving mitochondrial respiratory function.
31053639	dexamethasone	induce	the rate of hepatic	Using a stable isotope-labeling technique, we found that dexamethasone treatment induced the rate of hepatic
31151157	Thioacetamide	induce	lipid accumulation in the liver	Thioacetamide (TAA) is known to induce lipid accumulation in the liver.
31330194	dexamethasone	induce	steatosis	Meanwhile, dexamethasone induced steatosis could be ameliorated by silencing ENST00000608794 or expressing miR-15b-5p.
31463983	vitamin D	establish	an animal model of vitamin D deficiency	Mice were fed with vitamin D deficient diet, in which vitamin D was depleted for 12 weeks to establish an animal model of vitamin D deficiency.
31463983	vitamin D	induce	hepatic lipid accumulation	Results show that feeding mice with vitamin D deficient diet did not induce hepatic lipid accumulation.
31463983	vitamin D	reduce	alcohol-induced triacylglycerol (TAG) content	In contrast, vitamin D deficiency markedly reduced alcohol-induced triacylglycerol (TAG) content and prevented hepatic lipid accumulation.
31463983	vitamin D deficiency	reduce	alcohol-induced triacylglycerol (TAG) content	In contrast, vitamin D deficiency markedly reduced alcohol-induced triacylglycerol (TAG) content and prevented hepatic lipid accumulation.
31463983	vitamin D	prevent	hepatic lipid accumulation	In contrast, vitamin D deficiency markedly reduced alcohol-induced triacylglycerol (TAG) content and prevented hepatic lipid accumulation.
31463983	vitamin D deficiency	prevent	hepatic lipid accumulation	In contrast, vitamin D deficiency markedly reduced alcohol-induced triacylglycerol (TAG) content and prevented hepatic lipid accumulation.
31463983	vitamin D	attenuate	alcohol-induced sterol-regulated element-binding protein (SREBP)-1c activation, which regulates genes for hepatic fatty acid (FA) and TAG synthesis	Moreover, vitamin D deficiency significantly attenuated alcohol-induced sterol-regulated element-binding protein (SREBP)-1c activation, which regulates genes for hepatic fatty acid (FA) and TAG synthesis, and the expression of its target genes fatty acid synthase (Fasn) and acetyl-coenzyme- A carboxylase (Acc).
31463983	vitamin D	attenuate	the expression of its target genes fatty acid synthase (Fasn) and acetyl-coenzyme- A carboxylase (Acc)	Moreover, vitamin D deficiency significantly attenuated alcohol-induced sterol-regulated element-binding protein (SREBP)-1c activation, which regulates genes for hepatic fatty acid (FA) and TAG synthesis, and the expression of its target genes fatty acid synthase (Fasn) and acetyl-coenzyme- A carboxylase (Acc).
31463983	sterol-regulated element-binding protein (SREBP)-1c	regulate	genes for hepatic fatty acid (FA) and TAG synthesis	Moreover, vitamin D deficiency significantly attenuated alcohol-induced sterol-regulated element-binding protein (SREBP)-1c activation, which regulates genes for hepatic fatty acid (FA) and TAG synthesis, and the expression of its target genes fatty acid synthase (Fasn) and acetyl-coenzyme- A carboxylase (Acc).
31463983	vitamin D	alleviate	alcohol-induced downregulation of hepatic nuclear peroxisome proliferator-activated receptor (PPAR)α, which governs FA transport and β-oxidation	In addition, vitamin D deficiency alleviated alcohol-induced downregulation of hepatic nuclear peroxisome proliferator-activated receptor (PPAR)α, which governs FA transport and β-oxidation, and the expression of Carnitine palmitoyltransferase (Cpt)-1α, cytochrome P450, family 4, subfamily a, polypeptide (Cyp4a)10, and Cyp4a14, which are key enzymes for hepatic fatty acids β-oxidation and ω-oxidation.
31463983	hepatic nuclear peroxisome proliferator-activated receptor	govern	FA transport and β-oxidation	In addition, vitamin D deficiency alleviated alcohol-induced downregulation of hepatic nuclear peroxisome proliferator-activated receptor (PPAR)α, which governs FA transport and β-oxidation, and the expression of Carnitine palmitoyltransferase (Cpt)-1α, cytochrome P450, family 4, subfamily a, polypeptide (Cyp4a)10, and Cyp4a14, which are key enzymes for hepatic fatty acids β-oxidation and ω-oxidation.
31463983	Vitamin D	alleviate	acute alcohol-induced hepatic lipid accumulation	Vitamin D deficiency alleviates acute alcohol-induced hepatic lipid accumulation through inhibiting hepatic de novo fatty acid syntheses and promoting fatty acid β-oxidation and ω-oxidation.
31463983	Vitamin D	inhibit	hepatic de novo fatty acid syntheses	Vitamin D deficiency alleviates acute alcohol-induced hepatic lipid accumulation through inhibiting hepatic de novo fatty acid syntheses and promoting fatty acid β-oxidation and ω-oxidation.
31463983	Vitamin D	promote	fatty acid β-oxidation and ω-oxidation	Vitamin D deficiency alleviates acute alcohol-induced hepatic lipid accumulation through inhibiting hepatic de novo fatty acid syntheses and promoting fatty acid β-oxidation and ω-oxidation.
31470036	Bisphenol A	increase	cholesterol levels	Bisphenol A (BPA), a major plasticizers that are commonly used for lining of beverage or food-storage containers, has been shown to increase cholesterol levels with molecular mechanism not clear.
31470036	BPA	increase	cholesterol levels	Bisphenol A (BPA), a major plasticizers that are commonly used for lining of beverage or food-storage containers, has been shown to increase cholesterol levels with molecular mechanism not clear.
31470036	plasticizers	increase	cholesterol levels	Bisphenol A (BPA), a major plasticizers that are commonly used for lining of beverage or food-storage containers, has been shown to increase cholesterol levels with molecular mechanism not clear.
31470036	BPA	increase	hepatic cholesterol content	Exposure to low doses (50 and 500 μg/kg/day) of BPA increased hepatic cholesterol content and the expression levels of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and sterol regulatory element binding proteins-2 (SREBP-2).
31470036	BPA	decrease	the DNA methylation levels of SREBP-2	DNA methylation analysis further showed that mice exposed to low-dose BPA decreased the DNA methylation levels of SREBP-2.
31470036	DNA	decrease	the DNA methylation levels of SREBP-2	DNA methylation analysis further showed that mice exposed to low-dose BPA decreased the DNA methylation levels of SREBP-2.
31470036	BPA	increase	the expression levels of SREBP-1c and stearoyl-CoA desaturase 1 in the liver	Moreover, low doses of BPA exposure increased the expression levels of SREBP-1c and stearoyl-CoA desaturase 1 in the liver, and induced hepatic lipid synthesis and fat accumulation.
31470036	BPA	induce	hepatic lipid synthesis and fat accumulation	Moreover, low doses of BPA exposure increased the expression levels of SREBP-1c and stearoyl-CoA desaturase 1 in the liver, and induced hepatic lipid synthesis and fat accumulation.
31470036	low-dose	induce	hepatic cholesterol synthesis	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	BPA	induce	hepatic cholesterol synthesis	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	cholesterol	cause	cholesterol accumulation	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	low-dose	decrease	the DNA methylation levels of SREBP-2	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	BPA	decrease	the DNA methylation levels of SREBP-2	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	low-dose	induce	liver lipid synthesis and hepatic steatosis	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	BPA	induce	liver lipid synthesis and hepatic steatosis	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	low-dose	up-regulate	the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31470036	BPA	up-regulate	the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation	Our results suggest that low-dose BPA exposure could induce hepatic cholesterol synthesis through decreasing the DNA methylation levels of SREBP-2 and subsequently up-regulating the expression of genes related to cholesterol synthesis in the liver, which causes cholesterol accumulation and further induces liver lipid synthesis and hepatic steatosis.
31473330	steroid	modulate	multiple physiological processes in teleosts	Estradiol (E2) is a sex steroid hormone that modulates multiple physiological processes in teleosts.
31473330	E2	upregulate	TC, TG, LDL, and HDL	Simultaneously, the E2 injections tended to upregulate TC, TG, LDL, and HDL in the serum.
31473330	E2	show	a significantly higher expression of the VLDL assembly genes but depressed levels of LDLR and LRP1	The 50 mg/kg E2 group showed a significantly higher expression of the VLDL assembly genes but depressed levels of LDLR and LRP1.
31473330	ICI	inhibit	the expression of MTP, LPL, LRP1, CD36, FABP11a, ACO1 and FAS in tilapia livers	The ICI injection inhibited the expression of MTP, LPL, LRP1, CD36, FABP11a, ACO1 and FAS in tilapia livers.
31473330	E2	induce	deposition of lipids in the livers of hybrid tilapia	These results demonstrated that by stimulating the expression of genes associated with the VLDL assembly, inhibiting lipoprotein lipase and lipoprotein receptor-related genes and promoting the rate-limiting enzyme in the synthesis of the TG, E2 induced deposition of lipids in the livers of hybrid tilapia.
31473330	E2	stimulate	the expression of genes associated with the VLDL assembly	These results demonstrated that by stimulating the expression of genes associated with the VLDL assembly, inhibiting lipoprotein lipase and lipoprotein receptor-related genes and promoting the rate-limiting enzyme in the synthesis of the TG, E2 induced deposition of lipids in the livers of hybrid tilapia.
31473330	E2	inhibit	lipoprotein lipase and lipoprotein receptor-related genes	These results demonstrated that by stimulating the expression of genes associated with the VLDL assembly, inhibiting lipoprotein lipase and lipoprotein receptor-related genes and promoting the rate-limiting enzyme in the synthesis of the TG, E2 induced deposition of lipids in the livers of hybrid tilapia.
31473330	E2	promote	the rate-limiting enzyme in the synthesis of the TG	These results demonstrated that by stimulating the expression of genes associated with the VLDL assembly, inhibiting lipoprotein lipase and lipoprotein receptor-related genes and promoting the rate-limiting enzyme in the synthesis of the TG, E2 induced deposition of lipids in the livers of hybrid tilapia.
31473330	E2	provide	new clues to illustrate the sex steroid function in energy metabolism in livers	Overall, the results suggest a role for E2 in fish lipid metabolisms that provide new clues to illustrate the sex steroid function in energy metabolism in livers.
31491605	Mono-2-ethylhexyl phthalate	induce	lipid accumulation in hepatocytes	Mono-2-ethylhexyl phthalate (MEHP), as the major metabolite of Di-(2-ethylhexyl) phthalate (DEHP), can induce lipid accumulation in hepatocytes and further leads to non-alcoholic fatty liver disease (NAFLD), while the underlying mechanism is unclear.
31491605	MEHP	induce	lipid accumulation in hepatocytes	Mono-2-ethylhexyl phthalate (MEHP), as the major metabolite of Di-(2-ethylhexyl) phthalate (DEHP), can induce lipid accumulation in hepatocytes and further leads to non-alcoholic fatty liver disease (NAFLD), while the underlying mechanism is unclear.
31491605	DEHP	induce	lipid accumulation in hepatocytes	Mono-2-ethylhexyl phthalate (MEHP), as the major metabolite of Di-(2-ethylhexyl) phthalate (DEHP), can induce lipid accumulation in hepatocytes and further leads to non-alcoholic fatty liver disease (NAFLD), while the underlying mechanism is unclear.
31491605	Di-(2-ethylhexyl	induce	lipid accumulation in hepatocytes	Mono-2-ethylhexyl phthalate (MEHP), as the major metabolite of Di-(2-ethylhexyl) phthalate (DEHP), can induce lipid accumulation in hepatocytes and further leads to non-alcoholic fatty liver disease (NAFLD), while the underlying mechanism is unclear.
31491605	phthalate	induce	lipid accumulation in hepatocytes	Mono-2-ethylhexyl phthalate (MEHP), as the major metabolite of Di-(2-ethylhexyl) phthalate (DEHP), can induce lipid accumulation in hepatocytes and further leads to non-alcoholic fatty liver disease (NAFLD), while the underlying mechanism is unclear.
31491605	MEHP	promote	the lipid synthesis and accumulation in BRL-3A cells	As a result, MEHP promoted the lipid synthesis and accumulation in BRL-3A cells.
31491605	MEHP	down-regulate	the expression	MEHP down-regulated the expression and inhibited the activation of JAK2/STAT5.
31491605	MEHP	inhibit	the activation of JAK2/STAT5	MEHP down-regulated the expression and inhibited the activation of JAK2/STAT5.
31491605	MEHP	inhibit	JAK2/STAT5 pathway	Therefore, we concluded that MEHP led to lipid accumulation through inhibiting JAK2/STAT5 pathway, resulted in damaging liver parenchyma and NAFLD by aggravating oxidation stress.
31682409	Cd	induce	NAFLD	In this study, we established a chronic Cd-exposure mouse model mimicking the liver Cd deposition in middle-aged human population to determine whether the environmental Cd exposure can induce NAFLD.
31682409	Cd	cause	marked hepatic mitochondrial dysfunction and fatty acid oxidation deficiency, along with significant suppression of sirtuin 1 (SIRT1) signaling pathway in the liver	The Cd exposure caused marked hepatic mitochondrial dysfunction and fatty acid oxidation deficiency, along with significant suppression of sirtuin 1 (SIRT1) signaling pathway in the liver.
31682409	Cd	inhibit	the mitochondrial fatty acid oxidation in hepatocytes	In vitro study confirmed that Cd evidently inhibited the mitochondrial fatty acid oxidation in hepatocytes and that SIRT1 signaling was potentially involved in the process.
31682409	Cd	deserve	greater attention	Our findings suggest that exposure to environmental Cd is a tangible risk factor for NAFLD, and the induced public health risks deserve greater attention.
31857090	xanthine oxidase	exert	both inflammatory and oxidative effects	Increased activity of xanthine oxidase (XO) exerts both inflammatory and oxidative effects and has been implicated in metabolic derangements including non-alcoholic fatty liver disease.
31857090	xanthine	exert	both inflammatory and oxidative effects	Increased activity of xanthine oxidase (XO) exerts both inflammatory and oxidative effects and has been implicated in metabolic derangements including non-alcoholic fatty liver disease.
31857090	SCFAs	elicit	beneficial metabolic alterations in IR and related syndromes	Short chain fatty acids (SCFAs) elicit beneficial metabolic alterations in IR and related syndromes.
31857090	fatty acids (SCFAs	elicit	beneficial metabolic alterations in IR and related syndromes	Short chain fatty acids (SCFAs) elicit beneficial metabolic alterations in IR and related syndromes.
31857090	nicotine	increase	fasting plasma glucose, lactate, IR, plasma and hepatic TG, free fatty acid, TG/HDL-cholesterol ratio, lipid peroxidation, liver function enzymes, plasma and hepatic UA, XO and ADA activities	Conversely, exposure to nicotine increased fasting plasma glucose, lactate, IR, plasma and hepatic TG, free fatty acid, TG/HDL-cholesterol ratio, lipid peroxidation, liver function enzymes, plasma and hepatic UA, XO and ADA activities.
31857090	acetate	ameliorate	nicotine-induced effects	Concomitant treatment with acetate ameliorated nicotine-induced effects.
31857090	nicotine	enhance	XO activity	Taken together, these results indicate that nicotine exposure leads to excess deposition of lipid in the liver by enhancing XO activity.
31857090	acetate	confer	hepatoprotection	The results also imply that acetate confers hepatoprotection and is accompanied by decreased XO activity.
31866205	SFAs	maintain	cell metabolic hemostasis	However, epidemiological results demonstrate a latent benefit of SFAs, and it remains elusive whether a certain low level of SFAs is physiologically essential for maintaining cell metabolic hemostasis.
31866205	PA	induce	lipotoxic effects	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	PA	induce	lipotoxic effects	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	LPA	induce	lipotoxic effects	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	PA	increase	mitochondrial functions	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	LPA	increase	mitochondrial functions	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	PA	alleviate	the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
31866205	LPA	alleviate	the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl	Here, we demonstrate that although high-level PA (HPA) indeed induces lipotoxic effects in liver cells, low-level PA (LPA) increases mitochondrial functions and alleviates the injuries induced by HPA or hepatoxic agent carbon tetrachloride (CCl
32165129	valproate	impaired	lipid droplet disposal starting at 1 mM after incubation for 3 or 7 days	In previously fatty acid loaded HepaRG cells, valproate impaired lipid droplet disposal starting at 1 mM after incubation for 3 or 7 days.
32165129	Valproate	increase	the expression of genes associated with fatty acid import and triglyceride synthesis	Valproate increased the expression of genes associated with fatty acid import and triglyceride synthesis, but did not relevantly affect expression of genes engaged in fatty acid activation.
32165129	Valproate	affect	expression of genes engaged in fatty acid activation	Valproate increased the expression of genes associated with fatty acid import and triglyceride synthesis, but did not relevantly affect expression of genes engaged in fatty acid activation.
32165129	Valproate	impair	mitochondrial fatty acid metabolism	Valproate impaired mitochondrial fatty acid metabolism by inhibiting β-ketothiolase and the function of the electron transport chain, which was associated with increased mitochondrial reactive oxygen species production.
32165129	Valproate	inhibit	β-ketothiolase	Valproate impaired mitochondrial fatty acid metabolism by inhibiting β-ketothiolase and the function of the electron transport chain, which was associated with increased mitochondrial reactive oxygen species production.
32165129	Valproate	increase	the mitochondrial DNA copy number per HepaRG cell,	Valproate increased the mitochondrial DNA copy number per HepaRG cell, possibly as a consequence of impaired mitochondrial function.
32165129	Valproate	decrease	the hepatocellular mRNA and protein expression of the fatty acid binding protein 1 (FABP1) and of the microsomal triglyceride transfer protein (MTTP)	Valproate decreased the hepatocellular mRNA and protein expression of the fatty acid binding protein 1 (FABP1) and of the microsomal triglyceride transfer protein (MTTP) at 1 mM and increased the hepatocellular concentration of free fatty acids.
32165129	Valproate	increase	the hepatocellular concentration of free fatty acids	Valproate decreased the hepatocellular mRNA and protein expression of the fatty acid binding protein 1 (FABP1) and of the microsomal triglyceride transfer protein (MTTP) at 1 mM and increased the hepatocellular concentration of free fatty acids.
32165129	valproate	decrease	protein expression and excretion of ApoB100 in HepaRG cells	Furthermore, valproate decreased protein expression and excretion of ApoB100 in HepaRG cells at 1 mM, reflecting impaired formation and excretion of very low-density lipoprotein (VLDL).
32165129	valproate	reflect	impaired formation and excretion of very low-density lipoprotein (VLDL)	Furthermore, valproate decreased protein expression and excretion of ApoB100 in HepaRG cells at 1 mM, reflecting impaired formation and excretion of very low-density lipoprotein (VLDL).
32165129	valproate	increase	the hepatocellular triglyceride content	In conclusion, valproate increased the hepatocellular triglyceride content by multiple mechanisms, whereby impaired expression of FABP1 and MTTP as well as impaired VLDL formation and excretion appeared to be dominant.
32165129	Valproate	cause	cell death	Valproate caused cell death mainly by apoptosis, which may be a consequence of mitochondrial oxidative stress and increased hepatocellular concentration of free fatty acids.
32165129	Valproate	increase	hepatocellular concentration of free fatty acids	Valproate caused cell death mainly by apoptosis, which may be a consequence of mitochondrial oxidative stress and increased hepatocellular concentration of free fatty acids.
32231762	Mitochondrial	examine	High AA	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	decrease	mitochondrial activity ( High AA:	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	induce	triglyceride accumulation	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	induce	triglyceride accumulation	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	increase	oxidative stress	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	increase	oxidative stress	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	disrupt	mitochondrial functions	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	DHA	disrupt	mitochondrial functions	Mitochondrial activity and function were examined High AA:DHA ratio decreased mitochondrial activity ( High AA:DHA ratio induced triglyceride accumulation, increased oxidative stress and disrupted mitochondrial functions.
32231762	steroidal transcription factors	mediate	these effects	Stimulation of lipogenic and steroidal transcription factors may partly mediate these effects and contribute to NAFLD development.
32324591	SCD1	regulate	lipophagy in hepatic steatosis	To investigate the molecular mechanisms through which SCD1 regulates lipophagy in hepatic steatosis, the model of hepatic steatosis was established by inducing mouse primary hepatocytes with sodium palmitate and feeding C57BL/6 mice with HFD.
32324591	hepatic steatosis	investigate	the molecular mechanisms through which SCD1 regulates lipophagy in hepatic steatosis	To investigate the molecular mechanisms through which SCD1 regulates lipophagy in hepatic steatosis, the model of hepatic steatosis was established by inducing mouse primary hepatocytes with sodium palmitate and feeding C57BL/6 mice with HFD.
32324591	hepatic steatosis	induce	mouse primary hepatocytes with sodium palmitate and feeding C57BL/6 mice with HFD	To investigate the molecular mechanisms through which SCD1 regulates lipophagy in hepatic steatosis, the model of hepatic steatosis was established by inducing mouse primary hepatocytes with sodium palmitate and feeding C57BL/6 mice with HFD.
32324591	sodium palmitate-treated hepatocytes	increase	SCD1 expression, AMPK inactivation and defective lipophagy	Our results indicated that sodium palmitate-treated hepatocytes exhibited increased SCD1 expression, AMPK inactivation and defective lipophagy.
32324591	SCD1	reduce	lipid deposition	Inhibition of SCD1 expression in hepatocytes resulted in enhanced AMPK activity and lipophagy, and reduced lipid deposition.
32324591	hepatocytes	reduce	lipid deposition	Inhibition of SCD1 expression in hepatocytes resulted in enhanced AMPK activity and lipophagy, and reduced lipid deposition.
32324591	SCD1	regulate	lipophagy	SCD1 regulated lipophagy through AMPK to affect lipid metabolism in mouse primary hepatocytes.
32324591	SCD1	affect	lipid metabolism	SCD1 regulated lipophagy through AMPK to affect lipid metabolism in mouse primary hepatocytes.
32324591	CAY10566(an	decrease	hepatic steatosis and hepatic lipid droplet accumulation, as well as enhanced AMPK activity and lipophagy	Additionally, compared to HFD-fed mice, CAY10566(an SCD1-specific inhibitor)-treated mice exhibited significantly decreased hepatic steatosis and hepatic lipid droplet accumulation, as well as enhanced AMPK activity and lipophagy.
32324591	SCD1	ameliorate	hepatic steatosis	This study elucidated that SCD1 inhibition ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy, suggesting that the SCD1-AMPK-lipophagy pathway is a potential therapeutic target for NAFLD.
32324591	SCD1	induce	AMPK-mediated lipophagy	This study elucidated that SCD1 inhibition ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy, suggesting that the SCD1-AMPK-lipophagy pathway is a potential therapeutic target for NAFLD.
32410680	nicotinamide adenine dinucleotide	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days	Non-alcoholic fatty liver disease is often associated with obesity, insulin resistance, dyslipidemia, and the metabolic syndrome in addition to mitochondrial dysfunction and nicotinamide adenine dinucleotide (NAD 12 C57BL/6 mice were fed a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days.
32410680	NAD 12 C57BL/6	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days	Non-alcoholic fatty liver disease is often associated with obesity, insulin resistance, dyslipidemia, and the metabolic syndrome in addition to mitochondrial dysfunction and nicotinamide adenine dinucleotide (NAD 12 C57BL/6 mice were fed a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days.
32410680	nicotinamide adenine	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days	Non-alcoholic fatty liver disease is often associated with obesity, insulin resistance, dyslipidemia, and the metabolic syndrome in addition to mitochondrial dysfunction and nicotinamide adenine dinucleotide (NAD 12 C57BL/6 mice were fed a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days.
32410680	NAD	feed	a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days	Non-alcoholic fatty liver disease is often associated with obesity, insulin resistance, dyslipidemia, and the metabolic syndrome in addition to mitochondrial dysfunction and nicotinamide adenine dinucleotide (NAD 12 C57BL/6 mice were fed a control diet, or an intervention diet supplemented with 0.9% (w/w) tetradecylthiopropionic acid for 14 days.
32410680	tetradecylthiopropionic acid	induce	fatty liver accompanied by decreased mitochondrial fatty acid oxidation	Dietary treatment with tetradecylthiopropionic acid for 2 weeks induced fatty liver accompanied by decreased mitochondrial fatty acid oxidation.
32410680	NAD Fatty liver	decrease	the levels of kynurenine metabolites	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32410680	tetradecylthiopropionic acid	decrease	the levels of kynurenine metabolites	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32410680	NAD	decrease	the levels of kynurenine metabolites	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32410680	NAD Fatty liver	increase	the plasma levels of NAD	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32410680	tetradecylthiopropionic acid	increase	the plasma levels of NAD	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32410680	NAD	increase	the plasma levels of NAD	The liver content of the oxidized form of NAD Fatty liver induced by short-time treatment with tetradecylthiopropionic acid decreased the levels of kynurenine metabolites but increased the plasma levels of NAD
32493774	rapeseed	cause	hepatic steatosis in animals	Feeding of rapeseed (canola) oil with a high erucic acid concentration is known to cause hepatic steatosis in animals.
32493774	erucic acid	cause	hepatic steatosis in animals	Feeding of rapeseed (canola) oil with a high erucic acid concentration is known to cause hepatic steatosis in animals.
32493774	Mitochondrial fatty acid	play	a central role	Mitochondrial fatty acid oxidation plays a central role in liver lipid homeostasis, so it is possible that hepatic metabolism of erucic acid might decrease mitochondrial fatty acid oxidation.
32493774	fatty acid	play	a central role	Mitochondrial fatty acid oxidation plays a central role in liver lipid homeostasis, so it is possible that hepatic metabolism of erucic acid might decrease mitochondrial fatty acid oxidation.
32493774	erucic acid	decrease	mitochondrial fatty acid oxidation	Mitochondrial fatty acid oxidation plays a central role in liver lipid homeostasis, so it is possible that hepatic metabolism of erucic acid might decrease mitochondrial fatty acid oxidation.
32493774	peroxisomal	stimulate	malonyl-CoA formation in the liver	Using male Sprague-Dawley rats, along with biochemical and molecular biology approaches, we report here that peroxisomal β-oxidation of erucic acid stimulates malonyl-CoA formation in the liver and thereby suppresses mitochondrial fatty acid oxidation.
32493774	erucic acid	stimulate	malonyl-CoA formation in the liver	Using male Sprague-Dawley rats, along with biochemical and molecular biology approaches, we report here that peroxisomal β-oxidation of erucic acid stimulates malonyl-CoA formation in the liver and thereby suppresses mitochondrial fatty acid oxidation.
32493774	peroxisomal	suppress	mitochondrial fatty acid oxidation	Using male Sprague-Dawley rats, along with biochemical and molecular biology approaches, we report here that peroxisomal β-oxidation of erucic acid stimulates malonyl-CoA formation in the liver and thereby suppresses mitochondrial fatty acid oxidation.
32493774	erucic acid	suppress	mitochondrial fatty acid oxidation	Using male Sprague-Dawley rats, along with biochemical and molecular biology approaches, we report here that peroxisomal β-oxidation of erucic acid stimulates malonyl-CoA formation in the liver and thereby suppresses mitochondrial fatty acid oxidation.
32585865	DZA	increase	hepatocellular triglyceride accumulation, which was also evident by morphological visualization of larger-sized LDs	Overnight exposure to DZA treatment dose-dependently increased hepatocellular triglyceride accumulation, which was also evident by morphological visualization of larger-sized LDs.
32585865	triglycerides	accompany	increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size	The rise in triglycerides and LDs accompanied increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size.
32585865	LDs	accompany	increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size	The rise in triglycerides and LDs accompanied increases in mRNA and protein levels of several LD-associated proteins known to regulate LD number and size.
32585865	DZA	cause	a decline in the levels of lipases that prevent fat accumulation as well as	Furthermore, DZA treatment caused a decline in the levels of lipases that prevent fat accumulation as well as increased the expression of factors involved in lipogenesis and fatty acid mobilization.
32585865	DZA	prevent	fat accumulation as well as	Furthermore, DZA treatment caused a decline in the levels of lipases that prevent fat accumulation as well as increased the expression of factors involved in lipogenesis and fatty acid mobilization.
32585865	DZA	increase	the expression of factors involved in lipogenesis and fatty acid mobilization	Furthermore, DZA treatment caused a decline in the levels of lipases that prevent fat accumulation as well as increased the expression of factors involved in lipogenesis and fatty acid mobilization.
32585865	intracellular SAH	promote	fat accumulation in hepatocytes, which is similar to that seen after alcohol exposure	Collectively, our results indicate that the elevation of intracellular SAH is sufficient to promote fat accumulation in hepatocytes, which is similar to that seen after alcohol exposure.
32593710	Bisphenol	impair	glucose and lipid metabolism	Bisphenol (BP)-A exposure can impair glucose and lipid metabolism.
32593710	endocrine	modulate	these processes	However, it is unclear whether this endocrine disruptor (ED) modulates these processes in postmenopause, a period with organic changes that increase the risk for metabolic diseases.
32593710	endocrine	increase	the risk for metabolic diseases	However, it is unclear whether this endocrine disruptor (ED) modulates these processes in postmenopause, a period with organic changes that increase the risk for metabolic diseases.
32593710	BPA	cause	mild steatosis in OVX CBPA females	Furthermore, BPA caused mild steatosis in OVX CBPA females, increasing the hepatic total lipids and mRNAs for Srebf1, Scd1, Hspa5, Hyou1 and Atf6.
32593710	BPA	increase	the hepatic total lipids and mRNAs for Srebf1, Scd1, Hspa5, Hyou1 and Atf6	Furthermore, BPA caused mild steatosis in OVX CBPA females, increasing the hepatic total lipids and mRNAs for Srebf1, Scd1, Hspa5, Hyou1 and Atf6.
32593710	BPA	aggravate	hepatic steatosis in OVX mice	BPA aggravated hepatic steatosis in OVX mice.
32593710	BPA	cause	NAFLD progression, which was partly mediated by chronic ER stress and the TGF-β1 pathway	Especially when combined with a HFD, BPA caused NAFLD progression, which was partly mediated by chronic ER stress and the TGF-β1 pathway.
32623605	VPA	cause	liver toxicity and steatosis through mitochondrial dysfunction	Valproic acid (VPA) is a frequently prescribed anti-epileptic drug which is known to cause liver toxicity and steatosis through mitochondrial dysfunction.
32623605	VPA	affect	oxygen consumption rates (OCRs)	While 3 h VPA exposure did not affect oxygen consumption rates (OCRs) in PHHs, prolonged exposure (24-72 h) significantly reduced basal and maximal OCRs.
32623605	VPA	cause	mitochondrial dysfunction	Given that in particular prolonged VPA exposure is required to cause mitochondrial dysfunction, we investigated gene expression data after VPA exposure for 24, 48, 72 h and 72 h VPA followed by a 72 h washout period.
32623605	TFs	rescue	VPA-induced mitochondrial dysfunction	Lentiviral knock-down of one of the candidate TFs, C/EBPα, partly rescued VPA-induced mitochondrial dysfunction.
32623605	PHHs	identify	24 genuine C/EBPα target genes that are regulated in response to prolonged VPA exposure in PHHs	Furthermore, RNA-Seq analysis of shC/EBPα and shGFP control PHHs identified 24 genuine C/EBPα target genes that are regulated in response to prolonged VPA exposure in PHHs.
32687983	MC-LR	impact	liver health	The data suggested that MC-LR exposure and subsequent NLRP3 inflammasome activation in childhood could impact liver health in juveniles.
33007364	VPA	cause	steatosis	Valproic acid (VPA) is a widely prescribed antiepileptic drug, which may cause steatosis in the liver.
33022571	Phe	have	severe effects	Phenanthrene (Phe), among the most ubiquitous polycyclic aromatic hydrocarbons (PAHs) existing in nature and foodstuffs, has severe effects on hepatic lipids metabolism.
33022571	Phenanthrene	have	severe effects	Phenanthrene (Phe), among the most ubiquitous polycyclic aromatic hydrocarbons (PAHs) existing in nature and foodstuffs, has severe effects on hepatic lipids metabolism.
33022571	polycyclic aromatic hydrocarbons	have	severe effects	Phenanthrene (Phe), among the most ubiquitous polycyclic aromatic hydrocarbons (PAHs) existing in nature and foodstuffs, has severe effects on hepatic lipids metabolism.
33022571	chemicals	disturb	intestinal microbiota, which plays a vital role in lipids metabolism	For environmental chemicals can disturb intestinal microbiota, which plays a vital role in lipids metabolism, we hypothesized that oral exposure to Phe may disrupt the intestinal microbiota, leading to the induction of an abnormal inflammatory response and lipid metabolism dysfunction.
33022571	chemicals	play	a vital role	For environmental chemicals can disturb intestinal microbiota, which plays a vital role in lipids metabolism, we hypothesized that oral exposure to Phe may disrupt the intestinal microbiota, leading to the induction of an abnormal inflammatory response and lipid metabolism dysfunction.
33022571	Phe	disrupt	the intestinal microbiota	For environmental chemicals can disturb intestinal microbiota, which plays a vital role in lipids metabolism, we hypothesized that oral exposure to Phe may disrupt the intestinal microbiota, leading to the induction of an abnormal inflammatory response and lipid metabolism dysfunction.
33022571	Phe	induce	significant alteration in relative Bacteroidetes, Firmicutes and Proteobacteria abundance in male mice	Herein, male mice were orally exposed to Phe (0.05, 0.5 and 5 mg/kg/2d) for ten weeks and the results showed that long term exposure to Phe induced significant alteration in relative Bacteroidetes, Firmicutes and Proteobacteria abundance in male mice.
33022571	Phe	alter	the composition of gastrointestinal bacteria	These results demonstrated that environmental-level Phe altered the composition of gastrointestinal bacteria and subsequently induced hepatic lipid metabolism disorder.
33022571	Phe	induce	hepatic lipid metabolism disorder	These results demonstrated that environmental-level Phe altered the composition of gastrointestinal bacteria and subsequently induced hepatic lipid metabolism disorder.
33105604	insulin receptor	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice	We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice.
33105604	IGF-1 receptor	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice	We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice.
33105604	IGF1R	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice	We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice.
33105604	OSI-906	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice	We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice.
33105604	IR/IGF1R	induce	glucose intolerance, hepatic steatosis, and lipoatrophy in mice	We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual IR/IGF1R inhibitor, induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice.
33105604	Linagliptin	improve	OSI-906-induced hepatic steatosis	Linagliptin improved OSI-906-induced hepatic steatosis via an insulin-signaling-independent pathway, without altering glucose levels, free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy.
33105604	Linagliptin	alter	glucose levels	Linagliptin improved OSI-906-induced hepatic steatosis via an insulin-signaling-independent pathway, without altering glucose levels, free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy.
33105604	Linagliptin	alter	free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy	Linagliptin improved OSI-906-induced hepatic steatosis via an insulin-signaling-independent pathway, without altering glucose levels, free fatty acid levels, gluconeogenic gene expressions in the liver, or visceral fat atrophy.
33105604	linagliptin	improve	hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation	Thus, linagliptin improved hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation, suggesting the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions.
33105604	IGF1R	involve	gluconeogenesis, lipogenesis, or inflammation	Thus, linagliptin improved hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation, suggesting the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions.
33105604	linagliptin	suggest	the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions	Thus, linagliptin improved hepatic steatosis induced by IR and IGF1R inhibition via a previously unknown mechanism that did not involve gluconeogenesis, lipogenesis, or inflammation, suggesting the non-canonical actions of DPP-4 inhibitors in the treatment of hepatic steatosis under insulin-resistant conditions.
33184849	conjugated linoleic acid	induce	an enlarged liver, hepatic steatosis	We demonstrate that conjugated linoleic acid (CLA) when given to mice as a dietary supplement, induced an enlarged liver, hepatic steatosis, and increased plasma levels of fatty acid (FA), alanine transaminase, and triglycerides.
33184849	CLA	induce	an enlarged liver, hepatic steatosis	We demonstrate that conjugated linoleic acid (CLA) when given to mice as a dietary supplement, induced an enlarged liver, hepatic steatosis, and increased plasma levels of fatty acid (FA), alanine transaminase, and triglycerides.
33184849	GW6471	block	PPARα binding to Acaca and Acads	Bioinformatic analysis of PPARα ChIP-seq data set and ChIP-qPCR showed that GW6471 blocks PPARα binding to Acaca and Acads and abolishes the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes.
33184849	PPARα	block	PPARα binding to Acaca and Acads	Bioinformatic analysis of PPARα ChIP-seq data set and ChIP-qPCR showed that GW6471 blocks PPARα binding to Acaca and Acads and abolishes the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes.
33184849	GW6471	abolish	the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes	Bioinformatic analysis of PPARα ChIP-seq data set and ChIP-qPCR showed that GW6471 blocks PPARα binding to Acaca and Acads and abolishes the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes.
33184849	PPARα	abolish	the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes	Bioinformatic analysis of PPARα ChIP-seq data set and ChIP-qPCR showed that GW6471 blocks PPARα binding to Acaca and Acads and abolishes the PPARα-mediated local histone modifications of H3K27ac and H3K4me1 in CLA-treated hepatocytes.
33302084	glyphosate	raise	potential environmental threats and public health concerns	Residues of glyphosate (GLY) are widely detected in aquatic systems, raising potential environmental threats and public health concerns, but the mechanism underlying GLY-induced hepatotoxicity in fish has not been fully elucidated yet.
33302084	GLY	raise	potential environmental threats and public health concerns	Residues of glyphosate (GLY) are widely detected in aquatic systems, raising potential environmental threats and public health concerns, but the mechanism underlying GLY-induced hepatotoxicity in fish has not been fully elucidated yet.
33302084	pro-	clarify	their roles	Next, changes in oxidative stress biomarkers, gene expression levels of pro- and anti-inflammatory cytokines, and lipid metabolism-related parameters in collected samples were analyzed to clarify their roles in GLY-induced hepatic damage.
33302084	lipid	clarify	their roles	Next, changes in oxidative stress biomarkers, gene expression levels of pro- and anti-inflammatory cytokines, and lipid metabolism-related parameters in collected samples were analyzed to clarify their roles in GLY-induced hepatic damage.
33302084	samples	clarify	their roles	Next, changes in oxidative stress biomarkers, gene expression levels of pro- and anti-inflammatory cytokines, and lipid metabolism-related parameters in collected samples were analyzed to clarify their roles in GLY-induced hepatic damage.
33302084	Lipid	reduce	lipolysis-related gene expression levels, and resultant hepatic lipid accumulation	Lipid metabolism disorder was a late event during GLY exposure, as evidenced by overproduced hepatic free fatty acids, enhanced lipogenesis-related gene expression levels, reduced lipolysis-related gene expression levels, and resultant hepatic lipid accumulation.
33302084	GLY	induce	hepatotoxicity in fish	Collectively, these findings demonstrate that GLY induces hepatotoxicity in fish through involvement of oxidative stress, inflammatory response, and lipid metabolism disorder, which are intimately interrelated with each other during GLY exposure.
33449950	O-1	stimulate	adipose triglyceride lipase (ATGL)	Forkhead box O-1 (FoxO1) is one of the FoxO family members of transcription factors and can stimulate adipose triglyceride lipase (ATGL) and suppress its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver.
33449950	FoxO1	stimulate	adipose triglyceride lipase (ATGL)	Forkhead box O-1 (FoxO1) is one of the FoxO family members of transcription factors and can stimulate adipose triglyceride lipase (ATGL) and suppress its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver.
33449950	O-1	suppress	its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver	Forkhead box O-1 (FoxO1) is one of the FoxO family members of transcription factors and can stimulate adipose triglyceride lipase (ATGL) and suppress its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver.
33449950	FoxO1	suppress	its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver	Forkhead box O-1 (FoxO1) is one of the FoxO family members of transcription factors and can stimulate adipose triglyceride lipase (ATGL) and suppress its inhibitor G0/G1 switch gene 2 (G0S2) expression in the liver.
33449950	Palmitate	promote	lipid accumulation	Palmitate significantly promoted lipid accumulation but inhibited lipid decomposition in human HepG2 hepatoma cells.
33449950	Palmitate	inhibit	lipid decomposition in human HepG2 hepatoma cells	Palmitate significantly promoted lipid accumulation but inhibited lipid decomposition in human HepG2 hepatoma cells.
33449950	Palmitate	reduce	FoxO1, ATGL and its activator comparative gene identification-58 (CGI-58) expression	Palmitate also significantly reduced FoxO1, ATGL and its activator comparative gene identification-58 (CGI-58) expression but increased peroxisome proliferator-activated receptorγ (PPARγ) and its target gene G0S2 expression.
33449950	Palmitate	increase	peroxisome proliferator-activated receptorγ (PPARγ) and its target gene G0S2 expression	Palmitate also significantly reduced FoxO1, ATGL and its activator comparative gene identification-58 (CGI-58) expression but increased peroxisome proliferator-activated receptorγ (PPARγ) and its target gene G0S2 expression.
33449950	FoxO1	increase	palmitate-inhibited ATGL and CGI-58 expression	FoxO1 overexpression significantly increased palmitate-inhibited ATGL and CGI-58 expression but reduced palmitate-stimulated PPARγ and its target gene G0S2 expression.
33449950	FoxO1	reduce	palmitate-stimulated PPARγ and its target gene G0S2 expression	FoxO1 overexpression significantly increased palmitate-inhibited ATGL and CGI-58 expression but reduced palmitate-stimulated PPARγ and its target gene G0S2 expression.
33449950	FoxO1	inhibit	lipid accumulation	FoxO1 overexpression also inhibited lipid accumulation and promoted lipolysis in palmitate-treated hepatocytes.
33449950	FoxO1	promote	lipolysis in palmitate-treated hepatocytes	FoxO1 overexpression also inhibited lipid accumulation and promoted lipolysis in palmitate-treated hepatocytes.
33449950	FoxO1-mediated	protect	hepatocytes	Overall, these results indicate that FoxO1-mediated ATGL-dependent lipolysis may be an effective molecular mechanism in protecting hepatocytes from palmitate-induced fat accumulation.
33762794	body	demonstrate	the potential adverse effects of these substances, including its effect on the development of non-alcoholic fatty liver disease, as one of the most prevalent chronic liver diseases	A growing body of evidence has emerged demonstrating the potential adverse effects of these substances, including its effect on the development of non-alcoholic fatty liver disease, as one of the most prevalent chronic liver diseases.
33762794	μmol/L	increase	the triglyceride level	Perfluorobutanesulfonic acid at 200 μmol/L significantly increased the triglyceride level in the presence of fatty acid compared to the control, but not without fatty acid, which was abolished by a specific peroxisome proliferator-activated receptor gamma antagonist.
33900847	Uox-KO	develop	hyperuricemia and aberrant lipid-metabolism	In vivo, the Uox-KO mice spontaneously developed hyperuricemia and aberrant lipid-metabolism, concomitant with abnormal hepatic fat accumulation.
34128319	Rosiglitazone	exert	dual effects on liver steatosis	Rosiglitazone has been reported to exert dual effects on liver steatosis, and it could exacerbate liver steatosis in obese animal models, which was suggested to be closely related to the elevated hepatic expression of FABP4.
34128319	Rosiglitazone	exacerbate	liver steatosis	Rosiglitazone has been reported to exert dual effects on liver steatosis, and it could exacerbate liver steatosis in obese animal models, which was suggested to be closely related to the elevated hepatic expression of FABP4.
34128319	FABP4	alleviate	rosiglitazone-induced liver steatosis	This study aimed to investigate whether combined treatment with FABP4 inhibitor I-9 could alleviate rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
34128319	I-9	alleviate	rosiglitazone-induced liver steatosis	This study aimed to investigate whether combined treatment with FABP4 inhibitor I-9 could alleviate rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
34128319	FABP4 inhibitor I-9	alleviate	rosiglitazone-induced liver steatosis	This study aimed to investigate whether combined treatment with FABP4 inhibitor I-9 could alleviate rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
34128319	I-9	decrease	rosiglitazone-induced increase in serum FABP4 level	Results showed that combined treatment with I-9 decreased rosiglitazone-induced increase in serum FABP4 level and expression of lipogenic genes in liver, especially FABP4, and ameliorated liver steatosis in db/db mice.
34128319	FABP4	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	FABP4	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	I-9	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	I-9	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	FABP4 inhibitor I-9	ameliorate	rosiglitazone-exacerbated elevated serum FABP4 level	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	FABP4 inhibitor I-9	ameliorate	ectopic liver fat accumulation in obese diabetic db/db mice	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	FABP4	affect	its anti-diabetic efficacy	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	I-9	affect	its anti-diabetic efficacy	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34128319	FABP4 inhibitor I-9	affect	its anti-diabetic efficacy	We concluded that combined treatment with FABP4 inhibitor I-9 could ameliorate rosiglitazone-exacerbated elevated serum FABP4 level and ectopic liver fat accumulation in obese diabetic db/db mice without affecting its anti-diabetic efficacy.
34206460	clozapine	affect	weight,	This research investigated how clozapine affects weight, the bodily distribution of chromium, liver damage, fatty liver scores, glucose homeostasis, renal impairment, and retinopathy in mice fed a high fat diet (HFD).
34206460	chromium	feed	a high fat diet (HFD)	This research investigated how clozapine affects weight, the bodily distribution of chromium, liver damage, fatty liver scores, glucose homeostasis, renal impairment, and retinopathy in mice fed a high fat diet (HFD).
34206460	fatty liver	feed	a high fat diet (HFD)	This research investigated how clozapine affects weight, the bodily distribution of chromium, liver damage, fatty liver scores, glucose homeostasis, renal impairment, and retinopathy in mice fed a high fat diet (HFD).
34206460	glucose	feed	a high fat diet (HFD)	This research investigated how clozapine affects weight, the bodily distribution of chromium, liver damage, fatty liver scores, glucose homeostasis, renal impairment, and retinopathy in mice fed a high fat diet (HFD).
34206460	clozapine	gain	more weight	We discovered that obese mice treated with clozapine gained more weight and had greater kidney, liver, and retroperitoneal and epididymal fat pad masses; higher daily food efficiency; higher serum or hepatic triglyceride, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine levels; and higher hepatic lipid regulation marker expression than did the HFD-fed control mice.
34206460	clozapine	gain	higher daily food efficiency; higher serum or hepatic triglyceride, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine levels; and higher hepatic lipid regulation marker expression	We discovered that obese mice treated with clozapine gained more weight and had greater kidney, liver, and retroperitoneal and epididymal fat pad masses; higher daily food efficiency; higher serum or hepatic triglyceride, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine levels; and higher hepatic lipid regulation marker expression than did the HFD-fed control mice.
34206460	clozapine	exhibit	insulin resistance, poorer insulin sensitivity, greater glucose intolerance, and less Akt phosphorylation	Furthermore, the clozapine group mice exhibited insulin resistance, poorer insulin sensitivity, greater glucose intolerance, and less Akt phosphorylation; their GLUT4 expression was lower, they had renal damage, more reactive oxygen species, and IL-1 expression, and, finally, their levels of antioxidative enzymes (superoxide dismutase, glutathione peroxidase, and catalase) were lower.
34206460	clozapine	reduce	the thickness of retinal cell layers	Moreover, clozapine reduced the thickness of retinal cell layers and increased
34246650	Acetaminophen	aggravate	lipid deposition in the liver	Acetaminophen (APAP) is a commonly used painkiller, but it can aggravate lipid deposition in the liver and cause liver injury when used in fatty liver disease.
34246650	APAP	aggravate	lipid deposition in the liver	Acetaminophen (APAP) is a commonly used painkiller, but it can aggravate lipid deposition in the liver and cause liver injury when used in fatty liver disease.
34246650	Acetaminophen	cause	liver injury	Acetaminophen (APAP) is a commonly used painkiller, but it can aggravate lipid deposition in the liver and cause liver injury when used in fatty liver disease.
34246650	APAP	cause	liver injury	Acetaminophen (APAP) is a commonly used painkiller, but it can aggravate lipid deposition in the liver and cause liver injury when used in fatty liver disease.
34246650	CAV-1 stent-like domain	upregulate	CAV-1 expression	The CAV-1 stent-like domain (CSD, 82-101 amino acids of caveolin-1), used to upregulate CAV-1 expression, could reduce lipid accumulation and activate autophagy in AFL mice treated with APAP.
34246650	CSD	upregulate	CAV-1 expression	The CAV-1 stent-like domain (CSD, 82-101 amino acids of caveolin-1), used to upregulate CAV-1 expression, could reduce lipid accumulation and activate autophagy in AFL mice treated with APAP.
34246650	caveolin-1	upregulate	CAV-1 expression	The CAV-1 stent-like domain (CSD, 82-101 amino acids of caveolin-1), used to upregulate CAV-1 expression, could reduce lipid accumulation and activate autophagy in AFL mice treated with APAP.
34246650	CAV-1	interfere	RNA and	CAV-1 small interfering RNA and CAV1-overexpressing plasmid were separately transfected into A/O and APAP co-treated L02 cells.
34246650	CAV-1	co-treate	L02 cells	CAV-1 small interfering RNA and CAV1-overexpressing plasmid were separately transfected into A/O and APAP co-treated L02 cells.
34246650	CAV-1	reduce	lipid accumulation in L02 cells	The results show that CAV-1 reduced lipid accumulation in L02 cells and activated Pink-1/Parkin-related mitophagy.
34246650	CAV-1	activate	Pink-1/Parkin-related mitophagy	The results show that CAV-1 reduced lipid accumulation in L02 cells and activated Pink-1/Parkin-related mitophagy.
34267188	ethanol-fed	develop	severe hepatic steatosis and inflammation	In contrast, ethanol-fed Depdc5-LKO mice developed severe hepatic steatosis and inflammation.
34267188	Torin 1	suppress	mTORC1 activity	Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice.
34267188	Torin	suppress	mTORC1 activity	Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice.
34267188	Torin 1	ameliorate	ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice	Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice.
34267188	Torin	ameliorate	ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice	Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice.
34267188	fenofibrate	reverse	ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice	The pathological effect of sustained mTORC1 activity in ALD may be attributed to the suppression of peroxisome proliferator activated receptor α (PPARα), the master regulator of fatty acid oxidation in hepatocytes, because fenofibrate (PPARα agonist) treatment reverses ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice.
34267188	PPARα	reverse	ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice	The pathological effect of sustained mTORC1 activity in ALD may be attributed to the suppression of peroxisome proliferator activated receptor α (PPARα), the master regulator of fatty acid oxidation in hepatocytes, because fenofibrate (PPARα agonist) treatment reverses ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice.
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	induce	steatosis	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	TCDD	induce	steatosis	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	increase	hepatic uptake of dietary and mobilized peripheral fats	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	TCDD	increase	hepatic uptake of dietary and mobilized peripheral fats	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	inhibit	lipoprotein export	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	TCDD	inhibit	lipoprotein export	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	2,3,7,8-Tetrachlorodibenzo-p-dioxin	repress	β-oxidation	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	TCDD	repress	β-oxidation	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a persistent environmental contaminant, induces steatosis by increasing hepatic uptake of dietary and mobilized peripheral fats, inhibiting lipoprotein export, and repressing β-oxidation.
34344994	TCDD	repress	straight-chain fatty acid oxidation gene expression in mice	In this study, the mechanism of β-oxidation inhibition was investigated by testing the hypothesis that TCDD dose-dependently repressed straight-chain fatty acid oxidation gene expression in mice following oral gavage every 4 days for 28 days.
34344994	fatty acid	inhibit	the activity of short chain enoyl-CoA hydratase (ECHS1)	Collectively, the integration of metabolomics and RNA-seq data suggested TCDD induced a futile cycle of fatty acid activation and acyl-CoA hydrolysis resulting in incomplete β-oxidation, and the accumulation octenoyl-CoA levels that inhibited the activity of short chain enoyl-CoA hydratase (ECHS1).
34681291	TEB	cause	liver toxicity	Although TEB causes liver toxicity, its effects on cellular lipid accumulation are rarely investigated.
34681291	cellular lipid	cause	liver toxicity	Although TEB causes liver toxicity, its effects on cellular lipid accumulation are rarely investigated.
34681291	cells	show	lipid accumulation	HepG2 cells were exposed to 0-320 µM TEB for 1-24 h. TEB (20-80 µM, 24 h)-treated cells showed lipid accumulation.
34681291	HepG2 cells	show	lipid accumulation	HepG2 cells were exposed to 0-320 µM TEB for 1-24 h. TEB (20-80 µM, 24 h)-treated cells showed lipid accumulation.
34681291	TEB	increase	the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1	Further, TEB (20-80 µM, 1-12 h) increased the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1.
34681291	20-80	increase	the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1	Further, TEB (20-80 µM, 1-12 h) increased the nuclear translocation of peroxisome proliferator-activated receptors and the expression of lipid uptake and oxidation-related markers such as cluster of differentiation 36, fatty acid transport protein (FATP) 2, FATP5, and carnitine palmitoyltransferase 1.
34681291	20-80	induce	the loss of mitochondrial membrane potential and lower levels of microsomal triglyceride transfer protein in the cells	TEB (20-80 µM, 24 h) also induced the loss of mitochondrial membrane potential and lower levels of microsomal triglyceride transfer protein in the cells.
34681291	TEB	induce	lipid accumulation	Thus, TEB can induce lipid accumulation by altering the expression of lipid-metabolizing molecules and can therefore impair lipid metabolism.
34681291	TEB	alter	the expression of lipid-metabolizing molecules	Thus, TEB can induce lipid accumulation by altering the expression of lipid-metabolizing molecules and can therefore impair lipid metabolism.
34681291	TEB	impair	lipid metabolism	Thus, TEB can induce lipid accumulation by altering the expression of lipid-metabolizing molecules and can therefore impair lipid metabolism.
34685712	Cell	define	the causal role	Cell studies were conducted to define the causal role and underlying mechanism of FFA-activated mTORC1 signaling in hepatocellular cell injury.
34685712	Cell	underlie	mechanism of FFA-activated mTORC1 signaling in hepatocellular cell injury	Cell studies were conducted to define the causal role and underlying mechanism of FFA-activated mTORC1 signaling in hepatocellular cell injury.
34685712	palmitic acid	(pa)-induce	ER stress and suppression of LAMP2 and autophagy flux	We revealed that palmitic acid (PA)-induced ER stress and suppression of LAMP2 and autophagy flux were mTORC1-dependent as rapamycin reversed such deleterious effects.
34685712	rapamycin	reverse	such deleterious effects	We revealed that palmitic acid (PA)-induced ER stress and suppression of LAMP2 and autophagy flux were mTORC1-dependent as rapamycin reversed such deleterious effects.
34685712	ATF4	modulate	LAMP2	C/EBP homologous protein (CHOP) was downstream of ATF4 which partially modulated LAMP2.
34685712	rapamycin	attenuate	mTORC1 activation and ER stress,	Supplementation with rapamycin to alcohol-fed mice attenuated mTORC1 activation and ER stress, restored LAMP2 protein, and improved autophagy, leading to amelioration of alcohol-induced liver injury.
34685712	rapamycin	restore	LAMP2 protein	Supplementation with rapamycin to alcohol-fed mice attenuated mTORC1 activation and ER stress, restored LAMP2 protein, and improved autophagy, leading to amelioration of alcohol-induced liver injury.
34685712	rapamycin	improve	autophagy	Supplementation with rapamycin to alcohol-fed mice attenuated mTORC1 activation and ER stress, restored LAMP2 protein, and improved autophagy, leading to amelioration of alcohol-induced liver injury.
34685712	hepatic FFAs	play	a crucial role	This study demonstrates that hepatic FFAs play a crucial role in the pathogenesis of ALD by activating mTORC1 signaling, thereby inducing ER stress and suppressing LAMP2-autophagy flux pathway, which represents an important mechanism of FFA-induced hepatocellular injury.
34685712	FFAs	play	a crucial role	This study demonstrates that hepatic FFAs play a crucial role in the pathogenesis of ALD by activating mTORC1 signaling, thereby inducing ER stress and suppressing LAMP2-autophagy flux pathway, which represents an important mechanism of FFA-induced hepatocellular injury.
34685712	FFAs	represent	an important mechanism of FFA-induced hepatocellular injury	This study demonstrates that hepatic FFAs play a crucial role in the pathogenesis of ALD by activating mTORC1 signaling, thereby inducing ER stress and suppressing LAMP2-autophagy flux pathway, which represents an important mechanism of FFA-induced hepatocellular injury.
34685712	hepatic FFAs	activate	mTORC1 signaling	This study demonstrates that hepatic FFAs play a crucial role in the pathogenesis of ALD by activating mTORC1 signaling, thereby inducing ER stress and suppressing LAMP2-autophagy flux pathway, which represents an important mechanism of FFA-induced hepatocellular injury.
34685712	FFAs	activate	mTORC1 signaling	This study demonstrates that hepatic FFAs play a crucial role in the pathogenesis of ALD by activating mTORC1 signaling, thereby inducing ER stress and suppressing LAMP2-autophagy flux pathway, which represents an important mechanism of FFA-induced hepatocellular injury.
34801933	HepG2	enhance	lipid transport to the cell	The treatment of HepG2 with dexamethasone and palmitate enhanced lipid transport to the cell via increased especially FABPpm expression and resulted in the increased triacylglycerol (TAG), diacylglycerol (DAG) and ceramide deposition.
34801933	dexamethasone	enhance	lipid transport to the cell	The treatment of HepG2 with dexamethasone and palmitate enhanced lipid transport to the cell via increased especially FABPpm expression and resulted in the increased triacylglycerol (TAG), diacylglycerol (DAG) and ceramide deposition.
34801933	palmitate	enhance	lipid transport to the cell	The treatment of HepG2 with dexamethasone and palmitate enhanced lipid transport to the cell via increased especially FABPpm expression and resulted in the increased triacylglycerol (TAG), diacylglycerol (DAG) and ceramide deposition.
34801933	Dexamethasone	alter	FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG	Dexamethasone with palmitate treatment altered FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG and the diminished n-6 PUFA activity in DAG after prolonged exposure.
34801933	palmitate	alter	FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG	Dexamethasone with palmitate treatment altered FA composition resulting in the elevated n-3 polyunsaturated fatty acid (PUFA) activity in DAG and TAG and the diminished n-6 PUFA activity in DAG after prolonged exposure.
34801933	lipid	exacerbate	lipotoxicity in HepG2 cells	We may speculate that although protective lipid secretion into media and decrease in inflammatory FA precursors dexamethasone treatment exacerbated lipotoxicity in HepG2 cells.
34801933	FA	exacerbate	lipotoxicity in HepG2 cells	We may speculate that although protective lipid secretion into media and decrease in inflammatory FA precursors dexamethasone treatment exacerbated lipotoxicity in HepG2 cells.
34801933	dexamethasone	exacerbate	lipotoxicity in HepG2 cells	We may speculate that although protective lipid secretion into media and decrease in inflammatory FA precursors dexamethasone treatment exacerbated lipotoxicity in HepG2 cells.
34836271	GEN	inhibit	hepatic triglyceride accretion triggered by estrogen deficiency	Genistein (GEN) has been shown to significantly inhibit hepatic triglyceride accretion triggered by estrogen deficiency.
34836271	Genistein	inhibit	hepatic triglyceride accretion triggered by estrogen deficiency	Genistein (GEN) has been shown to significantly inhibit hepatic triglyceride accretion triggered by estrogen deficiency.
34836271	GEN	downregulate	the levels of genes and proteins involved in lipogenesis, such as sterol-regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FASN), and stearoyl-coenzyme A desaturase 1 (SCD1)	Meanwhile, GEN downregulated the levels of genes and proteins involved in lipogenesis, such as sterol-regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FASN), and stearoyl-coenzyme A desaturase 1 (SCD1), and upregulated the gene and protein levels of the regulation factors responsible for fatty acid β-oxidation, such as carnitine palmitoyltransferase 1α (CPT-1α) and peroxisome proliferator-activated receptor α (PPARα).
34836271	GEN	upregulate	the gene and protein levels of the regulation factors responsible for fatty acid β-oxidation, such as carnitine palmitoyltransferase 1α (CPT-1α) and peroxisome proliferator-activated receptor α (PPARα)	Meanwhile, GEN downregulated the levels of genes and proteins involved in lipogenesis, such as sterol-regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FASN), and stearoyl-coenzyme A desaturase 1 (SCD1), and upregulated the gene and protein levels of the regulation factors responsible for fatty acid β-oxidation, such as carnitine palmitoyltransferase 1α (CPT-1α) and peroxisome proliferator-activated receptor α (PPARα).
34836271	GEN	improve	hepatic lipid metabolism	In conclusion, GEN improved hepatic lipid metabolism by activating ERβ and further modulation of Akt/mTOR signals.
34836271	GEN	activate	ERβ and further modulation of Akt/mTOR signals	In conclusion, GEN improved hepatic lipid metabolism by activating ERβ and further modulation of Akt/mTOR signals.
34856412	farnesoid X receptor	regulate	fatty acid β-oxidation (FAO)	In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO).
34856412	FXR	regulate	fatty acid β-oxidation (FAO)	In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO).
34856412	farnesoid X receptor	maintain	bile acid, cholesterol and glucose homeostasis,	In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO).
34856412	FXR	maintain	bile acid, cholesterol and glucose homeostasis,	In addition to maintaining bile acid, cholesterol and glucose homeostasis, farnesoid X receptor (FXR) also regulates fatty acid β-oxidation (FAO).
34856412	fatty acids	use	an integrated metabolomic and transcriptomic analysis in control	To explore the different roles of hepatic and intestinal FXR in liver FAO, FAO-associated metabolites, including acylcarnitines and fatty acids, and FXR target gene mRNAs were profiled using an integrated metabolomic and transcriptomic analysis in control (Fxr
34856412	FXR	use	an integrated metabolomic and transcriptomic analysis in control	To explore the different roles of hepatic and intestinal FXR in liver FAO, FAO-associated metabolites, including acylcarnitines and fatty acids, and FXR target gene mRNAs were profiled using an integrated metabolomic and transcriptomic analysis in control (Fxr
34897744	fluoxetine	increase	the risk of metabolic diseases such as non-alcoholic fatty liver disease	However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease.
34897744	Fluoxetine	increase	hepatic lipid accumulation	Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro.
34897744	fluoxetine	alter	the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease	In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease.
34897744	Fluoxetine	increase	mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ	Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ
